Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,3102143,plasma half-life,"The plasma half-life is about 2 to 3 minutes; plasma clearance values reported vary from 216 to 3270 L/h, indicating extensive non-hepatic metabolism.",Clinical pharmacokinetics of glyceryl trinitrate following the use of systemic and topical preparations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3102143/),min,2 to 3,787,DB00727,Nitroglycerin
,3102143,plasma clearance,"The plasma half-life is about 2 to 3 minutes; plasma clearance values reported vary from 216 to 3270 L/h, indicating extensive non-hepatic metabolism.",Clinical pharmacokinetics of glyceryl trinitrate following the use of systemic and topical preparations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3102143/),[l] / [h],216 to 3270,788,DB00727,Nitroglycerin
,7669958,Need for,Need for NE during the loading infusion was 9.6 +/- 4.9 micrograms (mean +/- SEM) in group 1 and 41.6 +/- 7.6 micrograms in group 2 (p = 0.004).,Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669958/),μg,9.6,1547,DB00727,Nitroglycerin
,7669958,Need for,Need for NE during the loading infusion was 9.6 +/- 4.9 micrograms (mean +/- SEM) in group 1 and 41.6 +/- 7.6 micrograms in group 2 (p = 0.004).,Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669958/),μg,41.6,1548,DB00727,Nitroglycerin
,7669958,NE,Need for NE during the loading infusion was 9.6 +/- 4.9 micrograms (mean +/- SEM) in group 1 and 41.6 +/- 7.6 micrograms in group 2 (p = 0.004).,Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669958/),μg,9.6,1549,DB00727,Nitroglycerin
,7669958,NE,Need for NE during the loading infusion was 9.6 +/- 4.9 micrograms (mean +/- SEM) in group 1 and 41.6 +/- 7.6 micrograms in group 2 (p = 0.004).,Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669958/),μg,41.6,1550,DB00727,Nitroglycerin
,7669958,Need,Need for NE during the immediate post-CPB period was also higher in group 2 (16.0 +/- 10.4 micrograms in group 1 and 232.5 +/- 82.8 micrograms in group 2 (p = 0.002)).,Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669958/),μg,16.0,1551,DB00727,Nitroglycerin
,7669958,Need,Need for NE during the immediate post-CPB period was also higher in group 2 (16.0 +/- 10.4 micrograms in group 1 and 232.5 +/- 82.8 micrograms in group 2 (p = 0.002)).,Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669958/),μg,232.5,1552,DB00727,Nitroglycerin
,7669958,NE,Need for NE during the immediate post-CPB period was also higher in group 2 (16.0 +/- 10.4 micrograms in group 1 and 232.5 +/- 82.8 micrograms in group 2 (p = 0.002)).,Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669958/),μg,16.0,1553,DB00727,Nitroglycerin
,7669958,NE,Need for NE during the immediate post-CPB period was also higher in group 2 (16.0 +/- 10.4 micrograms in group 1 and 232.5 +/- 82.8 micrograms in group 2 (p = 0.002)).,Comparison of two different loading doses of milrinone for weaning from cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669958/),μg,232.5,1554,DB00727,Nitroglycerin
,3117068,duration of action,The duration of action of orally administered GTN in the dog depended on the concentration used and was between 15 and 360 min.,[The pharmacology and pharmacokinetics of glycerol-2-nitrate]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3117068/),min,15 and 360,1924,DB00727,Nitroglycerin
,3117068,half-life of elimination,"The half-life of elimination of G-2-N in the rat came to 2 h, and the substance was 100% bioavailable.",[The pharmacology and pharmacokinetics of glycerol-2-nitrate]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3117068/),h,2,1925,DB00727,Nitroglycerin
,1905575,clearance,"1,2-GDN was found to possess slightly higher clearance (32.3 vs 20.8 ml min-1 kg-1) and volume of distribution (695 vs 454 ml kg-1) than 1,3-GDN; however, the two metabolites exhibited similar mean residence times (22.0 vs 21.8 min).","Pharmacokinetic studies of the nitroglycerin metabolites, 1,2- and 1,3- glyceryl dinitrates, in the rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905575/),[ml] / [kg·min],32.3,3057,DB00727,Nitroglycerin
,1905575,clearance,"1,2-GDN was found to possess slightly higher clearance (32.3 vs 20.8 ml min-1 kg-1) and volume of distribution (695 vs 454 ml kg-1) than 1,3-GDN; however, the two metabolites exhibited similar mean residence times (22.0 vs 21.8 min).","Pharmacokinetic studies of the nitroglycerin metabolites, 1,2- and 1,3- glyceryl dinitrates, in the rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905575/),[ml] / [kg·min],20.8,3058,DB00727,Nitroglycerin
,1905575,volume of distribution,"1,2-GDN was found to possess slightly higher clearance (32.3 vs 20.8 ml min-1 kg-1) and volume of distribution (695 vs 454 ml kg-1) than 1,3-GDN; however, the two metabolites exhibited similar mean residence times (22.0 vs 21.8 min).","Pharmacokinetic studies of the nitroglycerin metabolites, 1,2- and 1,3- glyceryl dinitrates, in the rat. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905575/),[ml] / [kg],695,3059,DB00727,Nitroglycerin
,1905575,volume of distribution,"1,2-GDN was found to possess slightly higher clearance (32.3 vs 20.8 ml min-1 kg-1) and volume of distribution (695 vs 454 ml kg-1) than 1,3-GDN; however, the two metabolites exhibited similar mean residence times (22.0 vs 21.8 min).","Pharmacokinetic studies of the nitroglycerin metabolites, 1,2- and 1,3- glyceryl dinitrates, in the rat. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905575/),[ml] / [kg],454,3060,DB00727,Nitroglycerin
,1905575,mean residence times,"1,2-GDN was found to possess slightly higher clearance (32.3 vs 20.8 ml min-1 kg-1) and volume of distribution (695 vs 454 ml kg-1) than 1,3-GDN; however, the two metabolites exhibited similar mean residence times (22.0 vs 21.8 min).","Pharmacokinetic studies of the nitroglycerin metabolites, 1,2- and 1,3- glyceryl dinitrates, in the rat. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905575/),min,22.0,3061,DB00727,Nitroglycerin
,1905575,mean residence times,"1,2-GDN was found to possess slightly higher clearance (32.3 vs 20.8 ml min-1 kg-1) and volume of distribution (695 vs 454 ml kg-1) than 1,3-GDN; however, the two metabolites exhibited similar mean residence times (22.0 vs 21.8 min).","Pharmacokinetic studies of the nitroglycerin metabolites, 1,2- and 1,3- glyceryl dinitrates, in the rat. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905575/),min,21.8,3062,DB00727,Nitroglycerin
,15606445,C(max),"For L-arginine, mean C(max) +/- SEM (range) was 42 +/- 2.2 (28-63) microg ml(-1) and t(max) (range) was 0.88 (0.50-1.5) h.","An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606445/),[μg] / [ml],42,6659,DB00727,Nitroglycerin
,15606445,t(max),"For L-arginine, mean C(max) +/- SEM (range) was 42 +/- 2.2 (28-63) microg ml(-1) and t(max) (range) was 0.88 (0.50-1.5) h.","An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606445/),h,0.88,6660,DB00727,Nitroglycerin
,15606445,C(max),"For yohimbine, mean C(max) was 42 +/- 11 (2.8-128) ng ml(-1); t(max) was 0.57 (0.25-1.0) h; mean AUC(0,8 h) was 65 +/- 24 (5.4-332), ng ml(-1) h and t(1/2) was 1.0 +/- 0.34 (0.40-6.0) h.","An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606445/),[ng] / [ml],42,6661,DB00727,Nitroglycerin
,15606445,t(max),"For yohimbine, mean C(max) was 42 +/- 11 (2.8-128) ng ml(-1); t(max) was 0.57 (0.25-1.0) h; mean AUC(0,8 h) was 65 +/- 24 (5.4-332), ng ml(-1) h and t(1/2) was 1.0 +/- 0.34 (0.40-6.0) h.","An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606445/),h,0.57,6662,DB00727,Nitroglycerin
,15606445,"AUC(0,8 h)","For yohimbine, mean C(max) was 42 +/- 11 (2.8-128) ng ml(-1); t(max) was 0.57 (0.25-1.0) h; mean AUC(0,8 h) was 65 +/- 24 (5.4-332), ng ml(-1) h and t(1/2) was 1.0 +/- 0.34 (0.40-6.0) h.","An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606445/),[h·ng] / [ml],65,6663,DB00727,Nitroglycerin
,15606445,t(1/2),"For yohimbine, mean C(max) was 42 +/- 11 (2.8-128) ng ml(-1); t(max) was 0.57 (0.25-1.0) h; mean AUC(0,8 h) was 65 +/- 24 (5.4-332), ng ml(-1) h and t(1/2) was 1.0 +/- 0.34 (0.40-6.0) h.","An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606445/),h,1.0,6664,DB00727,Nitroglycerin
,6432996,Venous plasma clearance,Venous plasma clearance was found to be approximately 650 mL/kg and was independent of the intravenous or intra-arterial dose.,Pharmacokinetics of nitroglycerin after parenteral and oral dosing in the rat. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6432996/),[ml] / [kg],650,7812,DB00727,Nitroglycerin
,6432996,terminal half-life,A terminal half-life of approximately 15 min was observed after high intravenous bolus doses of nitroglycerin.,Pharmacokinetics of nitroglycerin after parenteral and oral dosing in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6432996/),min,15,7813,DB00727,Nitroglycerin
,32676977,half-life,"Peak and total plasma exposure to TRV250 increased in a dose-proportional manner following 0.1-30 mg SC doses, with the mean half-life ranging from 2.39 to 3.76 h.","A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32676977/),h,2.39 to 3.76,8936,DB00727,Nitroglycerin
,32676977,Oral bioavailability,"Oral bioavailability of TRV250 ranged from 14% (fasting) to 19% (fed) relative to SC dosing, while administration with food increased the AUC but decreased the rate of absorption as reflected by a modest delay in median time to maximum concentration and a slight reduction in maximum concentration.","A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32676977/),%,14,8937,DB00727,Nitroglycerin
,32676977,Oral bioavailability,"Oral bioavailability of TRV250 ranged from 14% (fasting) to 19% (fed) relative to SC dosing, while administration with food increased the AUC but decreased the rate of absorption as reflected by a modest delay in median time to maximum concentration and a slight reduction in maximum concentration.","A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32676977/),%,19,8938,DB00727,Nitroglycerin
,7873466,half-life,"Isosorbide 5-mononitrate has been studied in its own right as an antianginal agent: it is completely absorbed after oral administration; it has a half-life of around 4 hours, and oral standard and controlled-release formulations have been extensively studied.",Clinical pharmacokinetics of nitrates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7873466/),h,4,11964,DB00727,Nitroglycerin
,8145130,Css ratios,"The Css ratios of 1,2-GDN/GTN and 1,3-GDN/GTN yield overall averages of 31.5 +/- 17.2 and 5.47 +/- 3.19, respectively.",Pharmacokinetics and pharmacodynamics of nitroglycerin and its dinitrate metabolites in conscious dogs: intravenous infusion studies. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8145130/),,31.5,13921,DB00727,Nitroglycerin
,8145130,Css ratios,"The Css ratios of 1,2-GDN/GTN and 1,3-GDN/GTN yield overall averages of 31.5 +/- 17.2 and 5.47 +/- 3.19, respectively.",Pharmacokinetics and pharmacodynamics of nitroglycerin and its dinitrate metabolites in conscious dogs: intravenous infusion studies. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8145130/),,5.47,13922,DB00727,Nitroglycerin
,8145130,Css ratios,"Average Css ratios of metabolites 1,2-GDN/1,3-GDN were 5.78 +/- 1.23.",Pharmacokinetics and pharmacodynamics of nitroglycerin and its dinitrate metabolites in conscious dogs: intravenous infusion studies. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8145130/),,5.78,13923,DB00727,Nitroglycerin
,1708425,steady-state plasma t-PA clearance,"In a separate series of experiments, steady-state plasma t-PA clearance increased by 38% (407 +/- 49 vs. 294 +/- 42 ml/min; n = 8, P less than .02) during infusion of iloprost and recovered after its withdrawal.",A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1708425/),[ml] / [min],407,17408,DB00727,Nitroglycerin
,1708425,steady-state plasma t-PA clearance,"In a separate series of experiments, steady-state plasma t-PA clearance increased by 38% (407 +/- 49 vs. 294 +/- 42 ml/min; n = 8, P less than .02) during infusion of iloprost and recovered after its withdrawal.",A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1708425/),[ml] / [min],294,17409,DB00727,Nitroglycerin
,6411893,half-life,After intravenous administration the decline in plasma nitroglycerin concentration was biexponential with an initial half-life of 0.8 min (2-5 min postadministration) and a terminal half-life of 18 min (5-60 min postadministration).,Pharmacokinetics and bioavailability of intravenous and topical nitroglycerin in the rhesus monkey: estimate of percutaneous first-pass metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6411893/),min,0.8,19548,DB00727,Nitroglycerin
,6411893,terminal half-life,After intravenous administration the decline in plasma nitroglycerin concentration was biexponential with an initial half-life of 0.8 min (2-5 min postadministration) and a terminal half-life of 18 min (5-60 min postadministration).,Pharmacokinetics and bioavailability of intravenous and topical nitroglycerin in the rhesus monkey: estimate of percutaneous first-pass metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6411893/),min,18,19549,DB00727,Nitroglycerin
,6411893,alpha-phase half-life,"Plasma levels fit a biexponential curve with an alpha-phase half-life of 3.0 hr, a beta-phase half-life of 4.3 hr, and a lag time of 0.5 hr.",Pharmacokinetics and bioavailability of intravenous and topical nitroglycerin in the rhesus monkey: estimate of percutaneous first-pass metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6411893/),h,3.0,19550,DB00727,Nitroglycerin
,6411893,beta-phase half-life,"Plasma levels fit a biexponential curve with an alpha-phase half-life of 3.0 hr, a beta-phase half-life of 4.3 hr, and a lag time of 0.5 hr.",Pharmacokinetics and bioavailability of intravenous and topical nitroglycerin in the rhesus monkey: estimate of percutaneous first-pass metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6411893/),h,4.3,19551,DB00727,Nitroglycerin
,6411893,lag time,"Plasma levels fit a biexponential curve with an alpha-phase half-life of 3.0 hr, a beta-phase half-life of 4.3 hr, and a lag time of 0.5 hr.",Pharmacokinetics and bioavailability of intravenous and topical nitroglycerin in the rhesus monkey: estimate of percutaneous first-pass metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6411893/),h,0.5,19552,DB00727,Nitroglycerin
,6411893,absolute bioavailability,The absolute bioavailability of topical nitroglycerin was 56.6 +/- 5.8%.,Pharmacokinetics and bioavailability of intravenous and topical nitroglycerin in the rhesus monkey: estimate of percutaneous first-pass metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6411893/),%,56.6,19553,DB00727,Nitroglycerin
,2500248,rate,"The patch delivery of nitroglycerin was confirmed by patch residual results, which indicated nitroglycerin was released at a rate of 0.75 mg/cm2/24 hrs.",Performance of a new transdermal nitroglycerin adhesive patch formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2500248/),[mg] / [24·cm2·h],0.75,22913,DB00727,Nitroglycerin
,6769443,absorption rate (Kr,"The serum concentrations of nitroglycerin after application of nitroglycerin ointment (Neos-nitro-ointment), of a sustained-release capsule and a sublingual capsule demonstrated that the ointment shows a similar absorption rate (Kr = 0.957 h-1) as the sustained-release capsule (Kr = 1.244 h-1) and furthermore results in a twice as high serum concentration when given in a 30.4 mg nitroglycerin dose as compared to one sustained-release capsule.",[Pharmacokinetics and relative bioavailability of a nitroglycerin ointment formulation (author's transl)]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6769443/),1/[h],0.957,34180,DB00727,Nitroglycerin
,6769443,Kr,"The serum concentrations of nitroglycerin after application of nitroglycerin ointment (Neos-nitro-ointment), of a sustained-release capsule and a sublingual capsule demonstrated that the ointment shows a similar absorption rate (Kr = 0.957 h-1) as the sustained-release capsule (Kr = 1.244 h-1) and furthermore results in a twice as high serum concentration when given in a 30.4 mg nitroglycerin dose as compared to one sustained-release capsule.",[Pharmacokinetics and relative bioavailability of a nitroglycerin ointment formulation (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6769443/),1/[h],1.244,34181,DB00727,Nitroglycerin
,6769443,half-life of t1/2,Since the elimination rate of nitroglycerin was determined similar in all three application forms with a half-life of t1/2 approximately equal to 5 min it can be stated that the duration of effect after the application of ointment is longer than that of the sustained-release form based on the higher serum concentration.,[Pharmacokinetics and relative bioavailability of a nitroglycerin ointment formulation (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6769443/),min,5,34182,DB00727,Nitroglycerin
,3096133,Peak nitroglycerin concentrations,"Peak nitroglycerin concentrations were 5.1 +/- 4.3 ng/ml (arm), 6.2 +/- 6.0 ng/ml (chest), and 4.1 +/- 6.3 ng/ml (thigh).",Influence of skin site on bioavailability of nitroglycerin ointment in congestive heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3096133/),[ng] / [ml],5.1,37660,DB00727,Nitroglycerin
,3096133,Peak nitroglycerin concentrations,"Peak nitroglycerin concentrations were 5.1 +/- 4.3 ng/ml (arm), 6.2 +/- 6.0 ng/ml (chest), and 4.1 +/- 6.3 ng/ml (thigh).",Influence of skin site on bioavailability of nitroglycerin ointment in congestive heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3096133/),[ng] / [ml],6.2,37661,DB00727,Nitroglycerin
,3096133,Peak nitroglycerin concentrations,"Peak nitroglycerin concentrations were 5.1 +/- 4.3 ng/ml (arm), 6.2 +/- 6.0 ng/ml (chest), and 4.1 +/- 6.3 ng/ml (thigh).",Influence of skin site on bioavailability of nitroglycerin ointment in congestive heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3096133/),[ng] / [ml],4.1,37662,DB00727,Nitroglycerin
,7848349,areas under the curve from time 0 to the last,"For the areas under the curve from time 0 to the last quantifiable sample, AUC(O-Tlast), mean values of 1545 (test patch, n = 35) and 1686 h.pg/ml (reference patch, n = 35) were found.",Bioequivalence evaluation of two glyceryl trinitrate patches after 12-h usage in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848349/),[h·pg] / [ml],1545,43838,DB00727,Nitroglycerin
,7848349,areas under the curve from time 0 to the last,"For the areas under the curve from time 0 to the last quantifiable sample, AUC(O-Tlast), mean values of 1545 (test patch, n = 35) and 1686 h.pg/ml (reference patch, n = 35) were found.",Bioequivalence evaluation of two glyceryl trinitrate patches after 12-h usage in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848349/),[h·pg] / [ml],1686,43839,DB00727,Nitroglycerin
,7848349,AUC(O-Tlast),"For the areas under the curve from time 0 to the last quantifiable sample, AUC(O-Tlast), mean values of 1545 (test patch, n = 35) and 1686 h.pg/ml (reference patch, n = 35) were found.",Bioequivalence evaluation of two glyceryl trinitrate patches after 12-h usage in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848349/),[h·pg] / [ml],1545,43840,DB00727,Nitroglycerin
,7848349,AUC(O-Tlast),"For the areas under the curve from time 0 to the last quantifiable sample, AUC(O-Tlast), mean values of 1545 (test patch, n = 35) and 1686 h.pg/ml (reference patch, n = 35) were found.",Bioequivalence evaluation of two glyceryl trinitrate patches after 12-h usage in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848349/),[h·pg] / [ml],1686,43841,DB00727,Nitroglycerin
,7848349,peak glyceryl trinitrate plasma levels,"The corresponding peak glyceryl trinitrate plasma levels were 253 and 263 pg/ml, respectively; they were reached after 6.58 h (test patch) and 7.72 h (reference patch).",Bioequivalence evaluation of two glyceryl trinitrate patches after 12-h usage in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848349/),[pg] / [ml],253,43842,DB00727,Nitroglycerin
,7848349,peak glyceryl trinitrate plasma levels,"The corresponding peak glyceryl trinitrate plasma levels were 253 and 263 pg/ml, respectively; they were reached after 6.58 h (test patch) and 7.72 h (reference patch).",Bioequivalence evaluation of two glyceryl trinitrate patches after 12-h usage in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848349/),[pg] / [ml],263,43843,DB00727,Nitroglycerin
,3093667,active surface area,Both transdermal systems had an active surface area of 20 cm2.,Relative bioavailability of a new transdermal nitroglycerin delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3093667/),cm2,20,45041,DB00727,Nitroglycerin
,3093667,steady-state concentrations,"Mean steady-state concentrations of nitroglycerin were 182 and 224 pg/mL for I and II, respectively.",Relative bioavailability of a new transdermal nitroglycerin delivery system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3093667/),[pg] / [ml],182,45042,DB00727,Nitroglycerin
,3093667,steady-state concentrations,"Mean steady-state concentrations of nitroglycerin were 182 and 224 pg/mL for I and II, respectively.",Relative bioavailability of a new transdermal nitroglycerin delivery system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3093667/),[pg] / [ml],224,45043,DB00727,Nitroglycerin
>,9620098,trough:peak ratios,"Favorable hemodynamic and clinical profiles are reported, including high trough:peak ratios (> 80%), high oral bioavailability, and long elimination half-life (17-25 hrs) permitting once/day dosing.","Mibefradil, a pharmacologically distinct calcium antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620098/),%,80,47827,DB00727,Nitroglycerin
,9620098,elimination half-life,"Favorable hemodynamic and clinical profiles are reported, including high trough:peak ratios (> 80%), high oral bioavailability, and long elimination half-life (17-25 hrs) permitting once/day dosing.","Mibefradil, a pharmacologically distinct calcium antagonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620098/),h,17-25,47828,DB00727,Nitroglycerin
,6430939,apparent in vitro partitioning ratio,"Using this method, we found the apparent in vitro partitioning ratio of ISDN between erythrocyte and plasma in rat and human blood at 37 degrees C to be 0.22 and 0.13, respectively.","Determination of the partitioning, stability, and metabolite formation of isosorbide dinitrate in human and rat blood using an improved gas-liquid chromatographic assay. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6430939/),,0.22,52119,DB00727,Nitroglycerin
,6430939,apparent in vitro partitioning ratio,"Using this method, we found the apparent in vitro partitioning ratio of ISDN between erythrocyte and plasma in rat and human blood at 37 degrees C to be 0.22 and 0.13, respectively.","Determination of the partitioning, stability, and metabolite formation of isosorbide dinitrate in human and rat blood using an improved gas-liquid chromatographic assay. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6430939/),,0.13,52120,DB00727,Nitroglycerin
,7988629,tmax,The pharmacokinetic variables of the two formulations were very similar except for the longer tmax of 4.4 h for diltiazem CR in comparison to 2.9 h for the plain tablets.,Conventional and controlled release diltiazem. Bioavailability in healthy volunteers and anti-anginal effects in combination with metoprolol in stable angina pectoris. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988629/),h,4.4,52976,DB00727,Nitroglycerin
,7988629,tmax,The pharmacokinetic variables of the two formulations were very similar except for the longer tmax of 4.4 h for diltiazem CR in comparison to 2.9 h for the plain tablets.,Conventional and controlled release diltiazem. Bioavailability in healthy volunteers and anti-anginal effects in combination with metoprolol in stable angina pectoris. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988629/),h,2.9,52977,DB00727,Nitroglycerin
,7988629,relative bioavailability,The mean relative bioavailability of diltiazem CR in comparison with plain tablets was 1.14.,Conventional and controlled release diltiazem. Bioavailability in healthy volunteers and anti-anginal effects in combination with metoprolol in stable angina pectoris. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988629/),,1.14,52978,DB00727,Nitroglycerin
,7988629,maximum workload,"The clinical study showed that after four weeks on diltiazem CR 120 mg b.i.d. or diltiazem plain tablets 60 mg q.i.d. in addition to metoprolol, there were significant decreases in weekly anginal attacks from 11 to 5 attacks/week, the number of nitroglycerin tablets consumed from 6 to 3 tablets/week, and an increase in the maximum workload from 116 to 126 and 123 W for diltiazem CR and plain diltiazem tablets, respectively, as compared to placebo.",Conventional and controlled release diltiazem. Bioavailability in healthy volunteers and anti-anginal effects in combination with metoprolol in stable angina pectoris. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988629/),w,116,52979,DB00727,Nitroglycerin
,7988629,maximum workload,"The clinical study showed that after four weeks on diltiazem CR 120 mg b.i.d. or diltiazem plain tablets 60 mg q.i.d. in addition to metoprolol, there were significant decreases in weekly anginal attacks from 11 to 5 attacks/week, the number of nitroglycerin tablets consumed from 6 to 3 tablets/week, and an increase in the maximum workload from 116 to 126 and 123 W for diltiazem CR and plain diltiazem tablets, respectively, as compared to placebo.",Conventional and controlled release diltiazem. Bioavailability in healthy volunteers and anti-anginal effects in combination with metoprolol in stable angina pectoris. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988629/),w,126,52980,DB00727,Nitroglycerin
,7988629,maximum workload,"The clinical study showed that after four weeks on diltiazem CR 120 mg b.i.d. or diltiazem plain tablets 60 mg q.i.d. in addition to metoprolol, there were significant decreases in weekly anginal attacks from 11 to 5 attacks/week, the number of nitroglycerin tablets consumed from 6 to 3 tablets/week, and an increase in the maximum workload from 116 to 126 and 123 W for diltiazem CR and plain diltiazem tablets, respectively, as compared to placebo.",Conventional and controlled release diltiazem. Bioavailability in healthy volunteers and anti-anginal effects in combination with metoprolol in stable angina pectoris. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988629/),w,123,52981,DB00727,Nitroglycerin
,3108009,relative bioavailability,"The relative bioavailability of Nitroderm and Trinitrolong according to the pharmacokinetic data was 29% and 256%, respectively, of sublingual NG tablets.",New transdermal and transmucosal nitroglycerin delivery systems in patients with ischaemic heart disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108009/),%,29,62928,DB00727,Nitroglycerin
,3108009,relative bioavailability,"The relative bioavailability of Nitroderm and Trinitrolong according to the pharmacokinetic data was 29% and 256%, respectively, of sublingual NG tablets.",New transdermal and transmucosal nitroglycerin delivery systems in patients with ischaemic heart disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108009/),%,256,62929,DB00727,Nitroglycerin
,7650229,total amounts (AUCp x CLiv),"Mean (SD) total amounts (AUCp x CLiv) of GTN transdermally available after adjustment for 15N-labeled GTN clearance were 5.3 (2.1), 5.3 (2.0), and 5.4 (2.6) mg for Transderm-Nitro, Nitrodisc, and Nitro-Dur II, respectively.","Comparative pharmacokinetics and bioavailability of nitroglycerin and its metabolites from Transderm-Nitro, Nitrodisc, and Nitro-Dur II systems using a stable-isotope technique. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650229/),mg,5.3,67816,DB00727,Nitroglycerin
,7650229,total amounts (AUCp x CLiv),"Mean (SD) total amounts (AUCp x CLiv) of GTN transdermally available after adjustment for 15N-labeled GTN clearance were 5.3 (2.1), 5.3 (2.0), and 5.4 (2.6) mg for Transderm-Nitro, Nitrodisc, and Nitro-Dur II, respectively.","Comparative pharmacokinetics and bioavailability of nitroglycerin and its metabolites from Transderm-Nitro, Nitrodisc, and Nitro-Dur II systems using a stable-isotope technique. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650229/),mg,5.3,67817,DB00727,Nitroglycerin
,7650229,total amounts (AUCp x CLiv),"Mean (SD) total amounts (AUCp x CLiv) of GTN transdermally available after adjustment for 15N-labeled GTN clearance were 5.3 (2.1), 5.3 (2.0), and 5.4 (2.6) mg for Transderm-Nitro, Nitrodisc, and Nitro-Dur II, respectively.","Comparative pharmacokinetics and bioavailability of nitroglycerin and its metabolites from Transderm-Nitro, Nitrodisc, and Nitro-Dur II systems using a stable-isotope technique. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650229/),mg,5.4,67818,DB00727,Nitroglycerin
,7650229,AUC,"Mean (SD) AUC values for 1,2-GDN were 44.6 (15.8), 44.3 (16.1), and 42.8 (19.3) ng.h/mL for the 3 systems.","Comparative pharmacokinetics and bioavailability of nitroglycerin and its metabolites from Transderm-Nitro, Nitrodisc, and Nitro-Dur II systems using a stable-isotope technique. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650229/),[h·ng] / [ml],44.6,67819,DB00727,Nitroglycerin
,7650229,AUC,"Mean (SD) AUC values for 1,2-GDN were 44.6 (15.8), 44.3 (16.1), and 42.8 (19.3) ng.h/mL for the 3 systems.","Comparative pharmacokinetics and bioavailability of nitroglycerin and its metabolites from Transderm-Nitro, Nitrodisc, and Nitro-Dur II systems using a stable-isotope technique. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650229/),[h·ng] / [ml],44.3,67820,DB00727,Nitroglycerin
,7650229,AUC,"Mean (SD) AUC values for 1,2-GDN were 44.6 (15.8), 44.3 (16.1), and 42.8 (19.3) ng.h/mL for the 3 systems.","Comparative pharmacokinetics and bioavailability of nitroglycerin and its metabolites from Transderm-Nitro, Nitrodisc, and Nitro-Dur II systems using a stable-isotope technique. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650229/),[h·ng] / [ml],42.8,67821,DB00727,Nitroglycerin
,7650229,AUC,"Corresponding AUC values for 1,3-GDN were 9.3 (2.9), 9.7 (2.9), and 8.7 (3.0) ng.h/mL.","Comparative pharmacokinetics and bioavailability of nitroglycerin and its metabolites from Transderm-Nitro, Nitrodisc, and Nitro-Dur II systems using a stable-isotope technique. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650229/),[h·ng] / [ml],9.3,67822,DB00727,Nitroglycerin
,7650229,AUC,"Corresponding AUC values for 1,3-GDN were 9.3 (2.9), 9.7 (2.9), and 8.7 (3.0) ng.h/mL.","Comparative pharmacokinetics and bioavailability of nitroglycerin and its metabolites from Transderm-Nitro, Nitrodisc, and Nitro-Dur II systems using a stable-isotope technique. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650229/),[h·ng] / [ml],9.7,67823,DB00727,Nitroglycerin
,7650229,AUC,"Corresponding AUC values for 1,3-GDN were 9.3 (2.9), 9.7 (2.9), and 8.7 (3.0) ng.h/mL.","Comparative pharmacokinetics and bioavailability of nitroglycerin and its metabolites from Transderm-Nitro, Nitrodisc, and Nitro-Dur II systems using a stable-isotope technique. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650229/),[h·ng] / [ml],8.7,67824,DB00727,Nitroglycerin
,6406987,AUC,"Mean AUC for the 1/2"" and 1"" doses differed (648 vs 2003 ng.ml-1 min, p = 0.016), as did Cmax (4.6 vs 12.4 ng.ml-1, p = 0.022); however, there was no correlation between individual doses and AUCs.",Effect of dose and ointment application technique on nitroglycerin plasma concentrations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6406987/),[min·ng] / [ml],648,70850,DB00727,Nitroglycerin
,6406987,AUC,"Mean AUC for the 1/2"" and 1"" doses differed (648 vs 2003 ng.ml-1 min, p = 0.016), as did Cmax (4.6 vs 12.4 ng.ml-1, p = 0.022); however, there was no correlation between individual doses and AUCs.",Effect of dose and ointment application technique on nitroglycerin plasma concentrations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6406987/),[min·ng] / [ml],2003,70851,DB00727,Nitroglycerin
,6406987,Cmax,"Mean AUC for the 1/2"" and 1"" doses differed (648 vs 2003 ng.ml-1 min, p = 0.016), as did Cmax (4.6 vs 12.4 ng.ml-1, p = 0.022); however, there was no correlation between individual doses and AUCs.",Effect of dose and ointment application technique on nitroglycerin plasma concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6406987/),[ng] / [ml],4.6,70852,DB00727,Nitroglycerin
,6406987,Cmax,"Mean AUC for the 1/2"" and 1"" doses differed (648 vs 2003 ng.ml-1 min, p = 0.016), as did Cmax (4.6 vs 12.4 ng.ml-1, p = 0.022); however, there was no correlation between individual doses and AUCs.",Effect of dose and ointment application technique on nitroglycerin plasma concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6406987/),[ng] / [ml],12.4,70853,DB00727,Nitroglycerin
,3099808,bioavailability,The results of pharmacokinetic studies show that DNL bioavailability is 491 +/- 240% as compared to conventional oral IDN tablets.,"[Dinitrosorbilong--a new Soviet anti-angina preparation. Its comparative pharmacodynamic, pharmacokinetic and clinical study]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099808/),%,491,71935,DB00727,Nitroglycerin
,1429971,minimum quantifiable concentration,"The minimum quantifiable concentration for GTN, GDNs and GMNs is 0.4 ng/ml in plasma, with extraction recoveries for GMNs greater than 76% and for GTN and the GDNs greater than 95%.",Improved gas chromatographic assay for the simultaneous determination of nitroglycerin and its mono- and dinitrate metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1429971/),[ng] / [ml],0.4,74202,DB00727,Nitroglycerin
greater,1429971,extraction recoveries,"The minimum quantifiable concentration for GTN, GDNs and GMNs is 0.4 ng/ml in plasma, with extraction recoveries for GMNs greater than 76% and for GTN and the GDNs greater than 95%.",Improved gas chromatographic assay for the simultaneous determination of nitroglycerin and its mono- and dinitrate metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1429971/),%,76,74203,DB00727,Nitroglycerin
greater,1429971,extraction recoveries,"The minimum quantifiable concentration for GTN, GDNs and GMNs is 0.4 ng/ml in plasma, with extraction recoveries for GMNs greater than 76% and for GTN and the GDNs greater than 95%.",Improved gas chromatographic assay for the simultaneous determination of nitroglycerin and its mono- and dinitrate metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1429971/),%,95,74204,DB00727,Nitroglycerin
,1429971,Cmax ratios,"Following the intravenous administration of 1,2-GDN to five healthy male volunteers, 2-GMN/1-GMN Cmax ratios averaged 8.8:1, representing a highly selective but not specific formation of 2-GMN from the 1,2-GDN molecule.",Improved gas chromatographic assay for the simultaneous determination of nitroglycerin and its mono- and dinitrate metabolites. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1429971/),:,8.8,74205,DB00727,Nitroglycerin
,6243518,elimination half-life,"Serum levels rose linearly, with an average elimination half-life of about 10 hours after chronic oral dosing.",Atenolol: once-daily cardioselective beta blockade for angina pectoris. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6243518/),h,10,77502,DB00727,Nitroglycerin
,29489681,rate of drug administration,The rate of drug administration in all periods was 12 mL/hour for 30 minutes using an infusion pump.,A comparison of the pharmacokinetic and pharmacodynamic properties of nitroglycerin according to the composition of the administration set: A preliminary study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29489681/),[ml] / [h],12,79744,DB00727,Nitroglycerin
,2128865,AUC0-infinity,"There was no significant difference in the AUC0-infinity (A: 14.2 ng min/ml, B: 16.3 ng min/ml), but significant differences were obtained in Cmax (A: 1.41 ng/ml, B: 2.77 ng/ml, p less than 0.01) and tmax (A: 6.8 min, B: 3.9 min, p less than 0.01).",Bioaequivalence of sublingual glycerol trinitrate. Bioavailability and haemodynamic effects after application of a fluorochlorohydrocarbons-dependent spray and a new pumping system. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2128865/),[min·ng] / [ml],14.2,81268,DB00727,Nitroglycerin
,2128865,AUC0-infinity,"There was no significant difference in the AUC0-infinity (A: 14.2 ng min/ml, B: 16.3 ng min/ml), but significant differences were obtained in Cmax (A: 1.41 ng/ml, B: 2.77 ng/ml, p less than 0.01) and tmax (A: 6.8 min, B: 3.9 min, p less than 0.01).",Bioaequivalence of sublingual glycerol trinitrate. Bioavailability and haemodynamic effects after application of a fluorochlorohydrocarbons-dependent spray and a new pumping system. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2128865/),[min·ng] / [ml],16.3,81269,DB00727,Nitroglycerin
,2128865,Cmax,"There was no significant difference in the AUC0-infinity (A: 14.2 ng min/ml, B: 16.3 ng min/ml), but significant differences were obtained in Cmax (A: 1.41 ng/ml, B: 2.77 ng/ml, p less than 0.01) and tmax (A: 6.8 min, B: 3.9 min, p less than 0.01).",Bioaequivalence of sublingual glycerol trinitrate. Bioavailability and haemodynamic effects after application of a fluorochlorohydrocarbons-dependent spray and a new pumping system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2128865/),[ng] / [ml],1.41,81270,DB00727,Nitroglycerin
,2128865,Cmax,"There was no significant difference in the AUC0-infinity (A: 14.2 ng min/ml, B: 16.3 ng min/ml), but significant differences were obtained in Cmax (A: 1.41 ng/ml, B: 2.77 ng/ml, p less than 0.01) and tmax (A: 6.8 min, B: 3.9 min, p less than 0.01).",Bioaequivalence of sublingual glycerol trinitrate. Bioavailability and haemodynamic effects after application of a fluorochlorohydrocarbons-dependent spray and a new pumping system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2128865/),[ng] / [ml],2.77,81271,DB00727,Nitroglycerin
,2128865,tmax,"There was no significant difference in the AUC0-infinity (A: 14.2 ng min/ml, B: 16.3 ng min/ml), but significant differences were obtained in Cmax (A: 1.41 ng/ml, B: 2.77 ng/ml, p less than 0.01) and tmax (A: 6.8 min, B: 3.9 min, p less than 0.01).",Bioaequivalence of sublingual glycerol trinitrate. Bioavailability and haemodynamic effects after application of a fluorochlorohydrocarbons-dependent spray and a new pumping system. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2128865/),min,6.8,81272,DB00727,Nitroglycerin
,2128865,tmax,"There was no significant difference in the AUC0-infinity (A: 14.2 ng min/ml, B: 16.3 ng min/ml), but significant differences were obtained in Cmax (A: 1.41 ng/ml, B: 2.77 ng/ml, p less than 0.01) and tmax (A: 6.8 min, B: 3.9 min, p less than 0.01).",Bioaequivalence of sublingual glycerol trinitrate. Bioavailability and haemodynamic effects after application of a fluorochlorohydrocarbons-dependent spray and a new pumping system. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2128865/),min,3.9,81273,DB00727,Nitroglycerin
,2128865,EC50 A,"The GTN-response did not differ after both formulations (EC50 A: 0.441 ng/ml, EC50 B: 0.421 ng/ml), but significant differences were observed for tEC50 (A: 2.82 min, B: 1.05 min, p less than 0.01).",Bioaequivalence of sublingual glycerol trinitrate. Bioavailability and haemodynamic effects after application of a fluorochlorohydrocarbons-dependent spray and a new pumping system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2128865/),[ng] / [ml],0.441,81274,DB00727,Nitroglycerin
,2128865,EC50 B,"The GTN-response did not differ after both formulations (EC50 A: 0.441 ng/ml, EC50 B: 0.421 ng/ml), but significant differences were observed for tEC50 (A: 2.82 min, B: 1.05 min, p less than 0.01).",Bioaequivalence of sublingual glycerol trinitrate. Bioavailability and haemodynamic effects after application of a fluorochlorohydrocarbons-dependent spray and a new pumping system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2128865/),[ng] / [ml],0.421,81275,DB00727,Nitroglycerin
,2128865,tEC50,"The GTN-response did not differ after both formulations (EC50 A: 0.441 ng/ml, EC50 B: 0.421 ng/ml), but significant differences were observed for tEC50 (A: 2.82 min, B: 1.05 min, p less than 0.01).",Bioaequivalence of sublingual glycerol trinitrate. Bioavailability and haemodynamic effects after application of a fluorochlorohydrocarbons-dependent spray and a new pumping system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2128865/),min,2.82,81276,DB00727,Nitroglycerin
,2128865,tEC50,"The GTN-response did not differ after both formulations (EC50 A: 0.441 ng/ml, EC50 B: 0.421 ng/ml), but significant differences were observed for tEC50 (A: 2.82 min, B: 1.05 min, p less than 0.01).",Bioaequivalence of sublingual glycerol trinitrate. Bioavailability and haemodynamic effects after application of a fluorochlorohydrocarbons-dependent spray and a new pumping system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2128865/),min,1.05,81277,DB00727,Nitroglycerin
,6436032,steady-state plasma concentrations,"In 6 healthy volunteers, intravenous infusions of nitroglycerin 4.8 and 10.6 micrograms/min yielded mean steady-state plasma concentrations of 0.5 +/- 0.02 and 0.82 +/- 0.04 ng/ml as determined by a gas chromatographic/mass spectrometric method.",Studies of the bioavailability of nitroglycerin from a transdermal therapeutic system (Nitroderm TTS). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6436032/),[ng] / [ml],0.5,83168,DB00727,Nitroglycerin
,6436032,steady-state plasma concentrations,"In 6 healthy volunteers, intravenous infusions of nitroglycerin 4.8 and 10.6 micrograms/min yielded mean steady-state plasma concentrations of 0.5 +/- 0.02 and 0.82 +/- 0.04 ng/ml as determined by a gas chromatographic/mass spectrometric method.",Studies of the bioavailability of nitroglycerin from a transdermal therapeutic system (Nitroderm TTS). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6436032/),[ng] / [ml],0.82,83169,DB00727,Nitroglycerin
,2127557,peak plasma level,"In vivo, the drug was rapidly absorbed through the rat skin, with a peak plasma level of 581 +/- 151 and 265 +/- 62 ng/ml for the gel ointment and adhesive systems without a porous membrane, respectively.","Percutaneous absorption of 1,3-dinitroglycerin and a trial of pharmacokinetic analysis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2127557/),[ng] / [ml],581,83637,DB00727,Nitroglycerin
,2127557,peak plasma level,"In vivo, the drug was rapidly absorbed through the rat skin, with a peak plasma level of 581 +/- 151 and 265 +/- 62 ng/ml for the gel ointment and adhesive systems without a porous membrane, respectively.","Percutaneous absorption of 1,3-dinitroglycerin and a trial of pharmacokinetic analysis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2127557/),[ng] / [ml],265,83638,DB00727,Nitroglycerin
,2681004,denitration rate,"Since denitration is practically the only way of elimination, the denitration rate of the compounds is proportional to their total body clearance, which is 3.2 l/min for ISDN, 0.371 l/min for IS-2-MN and 0.124 l/min for IS-5-MN.",Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2681004/),[l] / [min],3.2,95220,DB00727,Nitroglycerin
,2681004,denitration rate,"Since denitration is practically the only way of elimination, the denitration rate of the compounds is proportional to their total body clearance, which is 3.2 l/min for ISDN, 0.371 l/min for IS-2-MN and 0.124 l/min for IS-5-MN.",Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2681004/),[l] / [min],0.371,95221,DB00727,Nitroglycerin
,2681004,denitration rate,"Since denitration is practically the only way of elimination, the denitration rate of the compounds is proportional to their total body clearance, which is 3.2 l/min for ISDN, 0.371 l/min for IS-2-MN and 0.124 l/min for IS-5-MN.",Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2681004/),[l] / [min],0.124,95222,DB00727,Nitroglycerin
,2681004,total body clearance,"Since denitration is practically the only way of elimination, the denitration rate of the compounds is proportional to their total body clearance, which is 3.2 l/min for ISDN, 0.371 l/min for IS-2-MN and 0.124 l/min for IS-5-MN.",Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2681004/),[l] / [min],3.2,95223,DB00727,Nitroglycerin
,2681004,total body clearance,"Since denitration is practically the only way of elimination, the denitration rate of the compounds is proportional to their total body clearance, which is 3.2 l/min for ISDN, 0.371 l/min for IS-2-MN and 0.124 l/min for IS-5-MN.",Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2681004/),[l] / [min],0.371,95224,DB00727,Nitroglycerin
,2681004,total body clearance,"Since denitration is practically the only way of elimination, the denitration rate of the compounds is proportional to their total body clearance, which is 3.2 l/min for ISDN, 0.371 l/min for IS-2-MN and 0.124 l/min for IS-5-MN.",Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2681004/),[l] / [min],0.124,95225,DB00727,Nitroglycerin
,2681004,terminal elimination half-life,"Their terminal elimination half-life is 63, 108 and 264 min respectively.",Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2681004/),min,63,95226,DB00727,Nitroglycerin
,2681004,terminal elimination half-life,"Their terminal elimination half-life is 63, 108 and 264 min respectively.",Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2681004/),min,108,95227,DB00727,Nitroglycerin
,2681004,terminal elimination half-life,"Their terminal elimination half-life is 63, 108 and 264 min respectively.",Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2681004/),min,264,95228,DB00727,Nitroglycerin
,3124139,detection limit,The detection limit was 0.1 ng/ml.,[Gas chromatographic determination of nitroglycerin in human plasma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3124139/),[ng] / [ml],0.1,95336,DB00727,Nitroglycerin
,6425569,arterial t1/2,"On the first day, the relationship between the arterial GTN concentration and the infusion rate was linear, the arterial t1/2 for GTN was short (1.9 min +/- 0.6) and there was an 80% arterial-venous extraction for GTN; these values were unchanged by five days of treatment with placebo.",Reproducibility of the pharmacokinetic-hemodynamic response to nitroglycerin in the dog: a model for studying the effects of chronic treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6425569/),min,1.9,97185,DB00727,Nitroglycerin
,6425569,arterial-venous extraction,"On the first day, the relationship between the arterial GTN concentration and the infusion rate was linear, the arterial t1/2 for GTN was short (1.9 min +/- 0.6) and there was an 80% arterial-venous extraction for GTN; these values were unchanged by five days of treatment with placebo.",Reproducibility of the pharmacokinetic-hemodynamic response to nitroglycerin in the dog: a model for studying the effects of chronic treatment. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6425569/),%,80,97186,DB00727,Nitroglycerin
less,3084757,bioavailable,Oral doses of nitroglycerin were less than 1% bioavailable.,The bioavailability of oral nitroglycerin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3084757/),%,1,98433,DB00727,Nitroglycerin
,3919988,ClB,"Forty minutes after the start of nitroglycerin therapy, ICG ClB fell from a baseline of 648 +/- 98 to 607 +/- 151 ml/min, and was further decreased to 578 +/- 98 ml/min 80 minutes after dosing.","Effects of hydralazine, nitroglycerin, and food on estimated hepatic blood flow. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919988/),[ml] / [min],648,100257,DB00727,Nitroglycerin
,3919988,ClB,"Forty minutes after the start of nitroglycerin therapy, ICG ClB fell from a baseline of 648 +/- 98 to 607 +/- 151 ml/min, and was further decreased to 578 +/- 98 ml/min 80 minutes after dosing.","Effects of hydralazine, nitroglycerin, and food on estimated hepatic blood flow. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919988/),[ml] / [min],607,100258,DB00727,Nitroglycerin
,3919988,ClB,"Forty minutes after the start of nitroglycerin therapy, ICG ClB fell from a baseline of 648 +/- 98 to 607 +/- 151 ml/min, and was further decreased to 578 +/- 98 ml/min 80 minutes after dosing.","Effects of hydralazine, nitroglycerin, and food on estimated hepatic blood flow. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919988/),[ml] / [min],578,100259,DB00727,Nitroglycerin
,3919988,ClB,"ICG ClB was 744 +/- 376, 721 +/- 218, and 763 +/- 195 ml/min at baseline, 40 minutes, and 80 minutes after dosing.","Effects of hydralazine, nitroglycerin, and food on estimated hepatic blood flow. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919988/),[ml] / [min],744,100260,DB00727,Nitroglycerin
,3919988,ClB,"ICG ClB was 744 +/- 376, 721 +/- 218, and 763 +/- 195 ml/min at baseline, 40 minutes, and 80 minutes after dosing.","Effects of hydralazine, nitroglycerin, and food on estimated hepatic blood flow. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919988/),[ml] / [min],721,100261,DB00727,Nitroglycerin
,3919988,ClB,"ICG ClB was 744 +/- 376, 721 +/- 218, and 763 +/- 195 ml/min at baseline, 40 minutes, and 80 minutes after dosing.","Effects of hydralazine, nitroglycerin, and food on estimated hepatic blood flow. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919988/),[ml] / [min],763,100262,DB00727,Nitroglycerin
,3919988,ClB,"After this meal, ICG ClB increased from 656 +/- 107 to 811 +/- 141 and 801 +/- 132 ml/min at 40 and 80 minutes after dosing.","Effects of hydralazine, nitroglycerin, and food on estimated hepatic blood flow. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919988/),[ml] / [min],656,100263,DB00727,Nitroglycerin
,3919988,ClB,"After this meal, ICG ClB increased from 656 +/- 107 to 811 +/- 141 and 801 +/- 132 ml/min at 40 and 80 minutes after dosing.","Effects of hydralazine, nitroglycerin, and food on estimated hepatic blood flow. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919988/),[ml] / [min],811,100264,DB00727,Nitroglycerin
,3919988,ClB,"After this meal, ICG ClB increased from 656 +/- 107 to 811 +/- 141 and 801 +/- 132 ml/min at 40 and 80 minutes after dosing.","Effects of hydralazine, nitroglycerin, and food on estimated hepatic blood flow. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919988/),[ml] / [min],801,100265,DB00727,Nitroglycerin
,6421295,maximum plasma levels,"Detectable GTN-levels were obtained up to 48 h after application, maximum plasma levels (836.1 +/- 124.2 pg/ml) were reached after 1.37 +/- 1.55 h.",[Bioavailability of glycerol trinitrate (nitroglycerin) from an ointment preparation]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6421295/),[pg] / [ml],836.1,105299,DB00727,Nitroglycerin
,6421295,plasma concentrations,12 h after application plasma concentrations of 154 +/- 20 pg/ml were observed which decreased to 65 +/- 13 pg/ml after 24 h.,[Bioavailability of glycerol trinitrate (nitroglycerin) from an ointment preparation]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6421295/),[pg] / [ml],154,105300,DB00727,Nitroglycerin
,6421295,plasma concentrations,12 h after application plasma concentrations of 154 +/- 20 pg/ml were observed which decreased to 65 +/- 13 pg/ml after 24 h.,[Bioavailability of glycerol trinitrate (nitroglycerin) from an ointment preparation]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6421295/),[pg] / [ml],65,105301,DB00727,Nitroglycerin
,3101710,bioavailability,The bioavailability of G-1-N in the rat and in the dog is practically 100%.,"[Hypotensive, antianginal action and pharmacokinetics of glyceryl-1-nitrate in rats and dogs]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3101710/),%,100,107989,DB00727,Nitroglycerin
,9239449,plasma concentrations,The plasma concentrations of GTN (mean) after the spray (dose: 0.8 mg GTN) reached a maximum of 3.96 ng/ml (range: 0.99-10.86) at 3.5 minutes (range: 2-5).,Studies on the bioavailability of glyceryl trinitrate after sublingual administration of spray and tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9239449/),[ng] / [ml],3.96,114896,DB00727,Nitroglycerin
,1772460,AUCo-t,"There was no significant difference (Wilcoxon's matched pairs signed rank test) in AUCo-t (A: 8.9 +/- 7.3 ng x h/ml; B: 8.3 +/- 7.6 ng x h/ml) and Cmax (A: 1.43 +/- 1.26 ng/ml; B: 1.13 +/- 1.06 ng/ml), but tmax was significantly shorter after application of the test product (A: 4.6 +/- 1.0 min; B: 6.7 +/- 2.7 min, p less than 0.01).",[Biologic availability and hemodynamic actions following administration of sublingual glycerol trinitrate. A new delivery system]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1772460/),[h·ng] / [ml],8.9,117762,DB00727,Nitroglycerin
,1772460,AUCo-t,"There was no significant difference (Wilcoxon's matched pairs signed rank test) in AUCo-t (A: 8.9 +/- 7.3 ng x h/ml; B: 8.3 +/- 7.6 ng x h/ml) and Cmax (A: 1.43 +/- 1.26 ng/ml; B: 1.13 +/- 1.06 ng/ml), but tmax was significantly shorter after application of the test product (A: 4.6 +/- 1.0 min; B: 6.7 +/- 2.7 min, p less than 0.01).",[Biologic availability and hemodynamic actions following administration of sublingual glycerol trinitrate. A new delivery system]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1772460/),[h·ng] / [ml],8.3,117763,DB00727,Nitroglycerin
,1772460,Cmax,"There was no significant difference (Wilcoxon's matched pairs signed rank test) in AUCo-t (A: 8.9 +/- 7.3 ng x h/ml; B: 8.3 +/- 7.6 ng x h/ml) and Cmax (A: 1.43 +/- 1.26 ng/ml; B: 1.13 +/- 1.06 ng/ml), but tmax was significantly shorter after application of the test product (A: 4.6 +/- 1.0 min; B: 6.7 +/- 2.7 min, p less than 0.01).",[Biologic availability and hemodynamic actions following administration of sublingual glycerol trinitrate. A new delivery system]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1772460/),[ng] / [ml],1.43,117764,DB00727,Nitroglycerin
,1772460,Cmax,"There was no significant difference (Wilcoxon's matched pairs signed rank test) in AUCo-t (A: 8.9 +/- 7.3 ng x h/ml; B: 8.3 +/- 7.6 ng x h/ml) and Cmax (A: 1.43 +/- 1.26 ng/ml; B: 1.13 +/- 1.06 ng/ml), but tmax was significantly shorter after application of the test product (A: 4.6 +/- 1.0 min; B: 6.7 +/- 2.7 min, p less than 0.01).",[Biologic availability and hemodynamic actions following administration of sublingual glycerol trinitrate. A new delivery system]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1772460/),[ng] / [ml],1.13,117765,DB00727,Nitroglycerin
,1772460,tmax,"There was no significant difference (Wilcoxon's matched pairs signed rank test) in AUCo-t (A: 8.9 +/- 7.3 ng x h/ml; B: 8.3 +/- 7.6 ng x h/ml) and Cmax (A: 1.43 +/- 1.26 ng/ml; B: 1.13 +/- 1.06 ng/ml), but tmax was significantly shorter after application of the test product (A: 4.6 +/- 1.0 min; B: 6.7 +/- 2.7 min, p less than 0.01).",[Biologic availability and hemodynamic actions following administration of sublingual glycerol trinitrate. A new delivery system]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1772460/),min,4.6,117766,DB00727,Nitroglycerin
,1772460,tmax,"There was no significant difference (Wilcoxon's matched pairs signed rank test) in AUCo-t (A: 8.9 +/- 7.3 ng x h/ml; B: 8.3 +/- 7.6 ng x h/ml) and Cmax (A: 1.43 +/- 1.26 ng/ml; B: 1.13 +/- 1.06 ng/ml), but tmax was significantly shorter after application of the test product (A: 4.6 +/- 1.0 min; B: 6.7 +/- 2.7 min, p less than 0.01).",[Biologic availability and hemodynamic actions following administration of sublingual glycerol trinitrate. A new delivery system]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1772460/),min,6.7,117767,DB00727,Nitroglycerin
,1772460,EC50A,"GTN response did not differ for both preparations (EC50A: 0.25 +/- 0.24 ng/ml; EC50 B: 0.34 +/- 0.36 ng/ml), coincident with tmax, tEC50 was significantly shorter after administration of (A) (A: 1.8 +/- 0.3 min, B: 2.7 +/- 1.0 min).",[Biologic availability and hemodynamic actions following administration of sublingual glycerol trinitrate. A new delivery system]. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1772460/),[ng] / [ml],0.25,117768,DB00727,Nitroglycerin
,1772460,EC50 B,"GTN response did not differ for both preparations (EC50A: 0.25 +/- 0.24 ng/ml; EC50 B: 0.34 +/- 0.36 ng/ml), coincident with tmax, tEC50 was significantly shorter after administration of (A) (A: 1.8 +/- 0.3 min, B: 2.7 +/- 1.0 min).",[Biologic availability and hemodynamic actions following administration of sublingual glycerol trinitrate. A new delivery system]. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1772460/),[ng] / [ml],0.34,117769,DB00727,Nitroglycerin
,1772460,tEC50,"GTN response did not differ for both preparations (EC50A: 0.25 +/- 0.24 ng/ml; EC50 B: 0.34 +/- 0.36 ng/ml), coincident with tmax, tEC50 was significantly shorter after administration of (A) (A: 1.8 +/- 0.3 min, B: 2.7 +/- 1.0 min).",[Biologic availability and hemodynamic actions following administration of sublingual glycerol trinitrate. A new delivery system]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1772460/),min,1.8,117770,DB00727,Nitroglycerin
,1772460,tEC50,"GTN response did not differ for both preparations (EC50A: 0.25 +/- 0.24 ng/ml; EC50 B: 0.34 +/- 0.36 ng/ml), coincident with tmax, tEC50 was significantly shorter after administration of (A) (A: 1.8 +/- 0.3 min, B: 2.7 +/- 1.0 min).",[Biologic availability and hemodynamic actions following administration of sublingual glycerol trinitrate. A new delivery system]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1772460/),min,2.7,117771,DB00727,Nitroglycerin
,3119815,F,Estimated F values (0.68-0.76) are comparable to values reported in Rhesus monkeys (0.80-0.84).,Transdermal bioavailability and first-pass skin metabolism: a preliminary evaluation with nitroglycerin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3119815/),,0.68-0.76,123279,DB00727,Nitroglycerin
,3119815,F,Estimated F values (0.68-0.76) are comparable to values reported in Rhesus monkeys (0.80-0.84).,Transdermal bioavailability and first-pass skin metabolism: a preliminary evaluation with nitroglycerin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3119815/),,0.80-0.84,123280,DB00727,Nitroglycerin
,7945539,plasma,"The plasma concentrations of 1,2-GDN and 1,3-GDN reached a maximum of 3.11 ng/ml (mean) (range: 1.14-5.44 ng/ml) and 0.70 ng/ml (mean) (range: 0.33-1.19 ng/ml) after 13.7 min (mean) (range: 8-40 min) and 17.6 min (mean) (range: 8-40 min).",Plasma concentrations of glyceryl trinitrate and its dinitrate metabolites after sublingual administration to volunteers. Simultaneous determination of glyceryl trinitrate and its dinitrate metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945539/),[ng] / [ml],3.11,123432,DB00727,Nitroglycerin
,7945539,t1/2,"The t1/2 values (mean) were 3.3, 35.5, and 38.1 min for GTN, 1,2-GDN, and 1,3-GDN, respectively.",Plasma concentrations of glyceryl trinitrate and its dinitrate metabolites after sublingual administration to volunteers. Simultaneous determination of glyceryl trinitrate and its dinitrate metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945539/),min,3.3,123433,DB00727,Nitroglycerin
,7945539,t1/2,"The t1/2 values (mean) were 3.3, 35.5, and 38.1 min for GTN, 1,2-GDN, and 1,3-GDN, respectively.",Plasma concentrations of glyceryl trinitrate and its dinitrate metabolites after sublingual administration to volunteers. Simultaneous determination of glyceryl trinitrate and its dinitrate metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945539/),min,35.5,123434,DB00727,Nitroglycerin
,7945539,t1/2,"The t1/2 values (mean) were 3.3, 35.5, and 38.1 min for GTN, 1,2-GDN, and 1,3-GDN, respectively.",Plasma concentrations of glyceryl trinitrate and its dinitrate metabolites after sublingual administration to volunteers. Simultaneous determination of glyceryl trinitrate and its dinitrate metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945539/),min,38.1,123435,DB00727,Nitroglycerin
,7945539,dinitrate ratio,The dinitrate ratio was estimated to be 4.1 (mean).,Plasma concentrations of glyceryl trinitrate and its dinitrate metabolites after sublingual administration to volunteers. Simultaneous determination of glyceryl trinitrate and its dinitrate metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945539/),,4.1,123436,DB00727,Nitroglycerin
,3935462,t1/2,GTN was rapidly metabolised (t1/2 3 min) to dinitro-metabolites and subsequently to the mononitronitrates in erythrocyte suspensions containing a therapeutic concentration of GTN (0.8-10 ng/ml).,Nitroglycerin disposition in human blood. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935462/),min,3,123945,DB00727,Nitroglycerin
,3935462,apparent erythrocyte-plasma partition coefficient,They had an apparent erythrocyte-plasma partition coefficient in the range 0.6 to 0.9.,Nitroglycerin disposition in human blood. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935462/),,0.6 to 0.9,123946,DB00727,Nitroglycerin
,3928505,release rate,The results show a satisfactory overall consistency of the data and indicate a release rate of 4.4 +/- SD 1.7 micrograms/min of bioavailable glyceryl trinitrate during the first hour of application of this transdermal system.,"Absolute bioavailability of glyceryl trinitrate from a transdermal system, assessed by digital plethysmography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3928505/),[μg] / [min],4.4,124450,DB00727,Nitroglycerin
,6423655,limit of detection,The limit of detection is 0.2 ng per injection.,Application of high-performance liquid chromatography with synchronized accumulating radioisotope detector to analysis of glyceryl trinitrate and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6423655/),[ng] / [injection],0.2,124451,DB00727,Nitroglycerin
,16526822,bioavailability,"Features and properties of 0.4% nitroglycerin (Rectogesic) rectal ointment Indication Pain associated with chronic anal fissures Mechanism of action Donor of nitric oxide Mediates relaxation of internal anal sphincter Dosage and administration Dosage 375 mg of 0.4% nitroglycerin rectal ointment, delivering nitroglycerin 1.5 mg Frequency Twice daily Route of administration Intra-anal Pharmacokinetic profile Mean bioavailability (0.2% nitroglycerin ointment, 0.75 mg nitroglycerin dose)50%Maximum plasma concentration 0.1 to >1 microg/L Volume of distribution approximate, equals 3 L/kg Clearance approximate, equals 1 L/kg/min Elimination half-life approximate, equals 3 min Most common adverse event Headache.",0.4% nitroglycerin ointment : in the treatment of chronic anal fissure pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16526822/),,0,125650,DB00727,Nitroglycerin
,16526822,50%Maximum plasma concentration,"Features and properties of 0.4% nitroglycerin (Rectogesic) rectal ointment Indication Pain associated with chronic anal fissures Mechanism of action Donor of nitric oxide Mediates relaxation of internal anal sphincter Dosage and administration Dosage 375 mg of 0.4% nitroglycerin rectal ointment, delivering nitroglycerin 1.5 mg Frequency Twice daily Route of administration Intra-anal Pharmacokinetic profile Mean bioavailability (0.2% nitroglycerin ointment, 0.75 mg nitroglycerin dose)50%Maximum plasma concentration 0.1 to >1 microg/L Volume of distribution approximate, equals 3 L/kg Clearance approximate, equals 1 L/kg/min Elimination half-life approximate, equals 3 min Most common adverse event Headache.",0.4% nitroglycerin ointment : in the treatment of chronic anal fissure pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16526822/),[μg] / [l],0.1 to >1,125651,DB00727,Nitroglycerin
,16526822,Volume of distribution,"Features and properties of 0.4% nitroglycerin (Rectogesic) rectal ointment Indication Pain associated with chronic anal fissures Mechanism of action Donor of nitric oxide Mediates relaxation of internal anal sphincter Dosage and administration Dosage 375 mg of 0.4% nitroglycerin rectal ointment, delivering nitroglycerin 1.5 mg Frequency Twice daily Route of administration Intra-anal Pharmacokinetic profile Mean bioavailability (0.2% nitroglycerin ointment, 0.75 mg nitroglycerin dose)50%Maximum plasma concentration 0.1 to >1 microg/L Volume of distribution approximate, equals 3 L/kg Clearance approximate, equals 1 L/kg/min Elimination half-life approximate, equals 3 min Most common adverse event Headache.",0.4% nitroglycerin ointment : in the treatment of chronic anal fissure pain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16526822/),[μg] / [l],0.1 to >1,125652,DB00727,Nitroglycerin
,16526822,Volume of distribution,"Features and properties of 0.4% nitroglycerin (Rectogesic) rectal ointment Indication Pain associated with chronic anal fissures Mechanism of action Donor of nitric oxide Mediates relaxation of internal anal sphincter Dosage and administration Dosage 375 mg of 0.4% nitroglycerin rectal ointment, delivering nitroglycerin 1.5 mg Frequency Twice daily Route of administration Intra-anal Pharmacokinetic profile Mean bioavailability (0.2% nitroglycerin ointment, 0.75 mg nitroglycerin dose)50%Maximum plasma concentration 0.1 to >1 microg/L Volume of distribution approximate, equals 3 L/kg Clearance approximate, equals 1 L/kg/min Elimination half-life approximate, equals 3 min Most common adverse event Headache.",0.4% nitroglycerin ointment : in the treatment of chronic anal fissure pain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16526822/),[l] / [kg],3,125653,DB00727,Nitroglycerin
,16526822,Clearance,"Features and properties of 0.4% nitroglycerin (Rectogesic) rectal ointment Indication Pain associated with chronic anal fissures Mechanism of action Donor of nitric oxide Mediates relaxation of internal anal sphincter Dosage and administration Dosage 375 mg of 0.4% nitroglycerin rectal ointment, delivering nitroglycerin 1.5 mg Frequency Twice daily Route of administration Intra-anal Pharmacokinetic profile Mean bioavailability (0.2% nitroglycerin ointment, 0.75 mg nitroglycerin dose)50%Maximum plasma concentration 0.1 to >1 microg/L Volume of distribution approximate, equals 3 L/kg Clearance approximate, equals 1 L/kg/min Elimination half-life approximate, equals 3 min Most common adverse event Headache.",0.4% nitroglycerin ointment : in the treatment of chronic anal fissure pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16526822/),[l] / [kg],3,125654,DB00727,Nitroglycerin
,16526822,Clearance,"Features and properties of 0.4% nitroglycerin (Rectogesic) rectal ointment Indication Pain associated with chronic anal fissures Mechanism of action Donor of nitric oxide Mediates relaxation of internal anal sphincter Dosage and administration Dosage 375 mg of 0.4% nitroglycerin rectal ointment, delivering nitroglycerin 1.5 mg Frequency Twice daily Route of administration Intra-anal Pharmacokinetic profile Mean bioavailability (0.2% nitroglycerin ointment, 0.75 mg nitroglycerin dose)50%Maximum plasma concentration 0.1 to >1 microg/L Volume of distribution approximate, equals 3 L/kg Clearance approximate, equals 1 L/kg/min Elimination half-life approximate, equals 3 min Most common adverse event Headache.",0.4% nitroglycerin ointment : in the treatment of chronic anal fissure pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16526822/),[l] / [kg·min],1,125655,DB00727,Nitroglycerin
,16526822,Elimination half-life,"Features and properties of 0.4% nitroglycerin (Rectogesic) rectal ointment Indication Pain associated with chronic anal fissures Mechanism of action Donor of nitric oxide Mediates relaxation of internal anal sphincter Dosage and administration Dosage 375 mg of 0.4% nitroglycerin rectal ointment, delivering nitroglycerin 1.5 mg Frequency Twice daily Route of administration Intra-anal Pharmacokinetic profile Mean bioavailability (0.2% nitroglycerin ointment, 0.75 mg nitroglycerin dose)50%Maximum plasma concentration 0.1 to >1 microg/L Volume of distribution approximate, equals 3 L/kg Clearance approximate, equals 1 L/kg/min Elimination half-life approximate, equals 3 min Most common adverse event Headache.",0.4% nitroglycerin ointment : in the treatment of chronic anal fissure pain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16526822/),[l] / [kg·min],1,125656,DB00727,Nitroglycerin
,16526822,Elimination half-life,"Features and properties of 0.4% nitroglycerin (Rectogesic) rectal ointment Indication Pain associated with chronic anal fissures Mechanism of action Donor of nitric oxide Mediates relaxation of internal anal sphincter Dosage and administration Dosage 375 mg of 0.4% nitroglycerin rectal ointment, delivering nitroglycerin 1.5 mg Frequency Twice daily Route of administration Intra-anal Pharmacokinetic profile Mean bioavailability (0.2% nitroglycerin ointment, 0.75 mg nitroglycerin dose)50%Maximum plasma concentration 0.1 to >1 microg/L Volume of distribution approximate, equals 3 L/kg Clearance approximate, equals 1 L/kg/min Elimination half-life approximate, equals 3 min Most common adverse event Headache.",0.4% nitroglycerin ointment : in the treatment of chronic anal fissure pain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16526822/),min,3,125657,DB00727,Nitroglycerin
,3932795,t1/2,"The mean values are: t1/2 = 9.2 min; V beta = 3.8 L/kg, Cltot = 238 ml/kg.",Disposition of nitroglycerin in the beagle dog after intravenous and buccal administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932795/),min,9.2,127581,DB00727,Nitroglycerin
,3932795,V beta,"The mean values are: t1/2 = 9.2 min; V beta = 3.8 L/kg, Cltot = 238 ml/kg.",Disposition of nitroglycerin in the beagle dog after intravenous and buccal administration. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932795/),[l] / [kg],3.8,127582,DB00727,Nitroglycerin
,3932795,Cltot,"The mean values are: t1/2 = 9.2 min; V beta = 3.8 L/kg, Cltot = 238 ml/kg.",Disposition of nitroglycerin in the beagle dog after intravenous and buccal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932795/),[ml] / [kg],238,127583,DB00727,Nitroglycerin
,3932795,bioavailability,The bioavailability buccally is 47%.,Disposition of nitroglycerin in the beagle dog after intravenous and buccal administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932795/),%,47,127584,DB00727,Nitroglycerin
,6414501,time constants,"A one compartment model fitted to haemodynamic and GTN data revealed time constants (+/- approximate standard error) for SPA, PCWP, RAP and GTN of 8.2 (3.4), 9.7 (3.0), 8.1 (3.8) and 8.1 (1.9 respectively.",Steady state pharmacokinetic haemodynamic studies of intravenous nitroglycerin in congestive cardiac failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6414501/),,8.2,137714,DB00727,Nitroglycerin
,6414501,time constants,"A one compartment model fitted to haemodynamic and GTN data revealed time constants (+/- approximate standard error) for SPA, PCWP, RAP and GTN of 8.2 (3.4), 9.7 (3.0), 8.1 (3.8) and 8.1 (1.9 respectively.",Steady state pharmacokinetic haemodynamic studies of intravenous nitroglycerin in congestive cardiac failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6414501/),,9.7,137715,DB00727,Nitroglycerin
,6414501,time constants,"A one compartment model fitted to haemodynamic and GTN data revealed time constants (+/- approximate standard error) for SPA, PCWP, RAP and GTN of 8.2 (3.4), 9.7 (3.0), 8.1 (3.8) and 8.1 (1.9 respectively.",Steady state pharmacokinetic haemodynamic studies of intravenous nitroglycerin in congestive cardiac failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6414501/),,8.1,137716,DB00727,Nitroglycerin
,6414501,time constants,"A one compartment model fitted to haemodynamic and GTN data revealed time constants (+/- approximate standard error) for SPA, PCWP, RAP and GTN of 8.2 (3.4), 9.7 (3.0), 8.1 (3.8) and 8.1 (1.9 respectively.",Steady state pharmacokinetic haemodynamic studies of intravenous nitroglycerin in congestive cardiac failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6414501/),,8.1,137717,DB00727,Nitroglycerin
,6414501,Clearance,Clearance for GTN was 6.2 +/- 2.7 (s.d.) 1 min.,Steady state pharmacokinetic haemodynamic studies of intravenous nitroglycerin in congestive cardiac failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6414501/),1·min,6.2,137718,DB00727,Nitroglycerin
,6414501,time constant,These data demonstrate steady state concentration of GTN is approached asymptotically with a time constant of 8.1 min during i.v. infusion of 21 micrograms/min.,Steady state pharmacokinetic haemodynamic studies of intravenous nitroglycerin in congestive cardiac failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6414501/),min,8.1,137719,DB00727,Nitroglycerin
,1550909,relative bioavailability,The relative bioavailability of the tablets in comparison with the oral solution was 70 per cent based on metabolite concentrations.,Pharmacokinetics of nitroglycerin and its metabolites after administration of sustained-release tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1550909/),%,70,137916,DB00727,Nitroglycerin
,6101155,apparent plasma clearance,"Generally, however, plasma nitroglycerin disposition was characterized by: (a) a large apparent plasma clearance (0.3-1 liter/min/kg), (b) a large volume of distribution (approximately 3 liters/kg), and (c) a rapid plasma half-life (approximately 3 min).",Nitroglycerin pharmacokinetics after intravenous infusion in normal subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6101155/),[l] / [kg·min],0.3-1,139763,DB00727,Nitroglycerin
,6101155,volume of distribution,"Generally, however, plasma nitroglycerin disposition was characterized by: (a) a large apparent plasma clearance (0.3-1 liter/min/kg), (b) a large volume of distribution (approximately 3 liters/kg), and (c) a rapid plasma half-life (approximately 3 min).",Nitroglycerin pharmacokinetics after intravenous infusion in normal subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6101155/),[l] / [kg],3,139764,DB00727,Nitroglycerin
,6101155,plasma half-life,"Generally, however, plasma nitroglycerin disposition was characterized by: (a) a large apparent plasma clearance (0.3-1 liter/min/kg), (b) a large volume of distribution (approximately 3 liters/kg), and (c) a rapid plasma half-life (approximately 3 min).",Nitroglycerin pharmacokinetics after intravenous infusion in normal subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6101155/),min,3,139765,DB00727,Nitroglycerin
,3932639,infusion rates,"Generally, at 0, 40, 80, and 120 min, the infusion rates were adjusted to 10, 20, 40, and 10 micrograms/min, respectively.",Dose dependent pharmacokinetics of nitroglycerin after multiple intravenous infusions in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932639/),,20,141398,DB00727,Nitroglycerin
,3932639,infusion rates,"Generally, at 0, 40, 80, and 120 min, the infusion rates were adjusted to 10, 20, 40, and 10 micrograms/min, respectively.",Dose dependent pharmacokinetics of nitroglycerin after multiple intravenous infusions in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932639/),,40,141399,DB00727,Nitroglycerin
,3932639,infusion rates,"Generally, at 0, 40, 80, and 120 min, the infusion rates were adjusted to 10, 20, 40, and 10 micrograms/min, respectively.",Dose dependent pharmacokinetics of nitroglycerin after multiple intravenous infusions in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932639/),,10,141400,DB00727,Nitroglycerin
,3932639,plasma concentrations,"Steady-state nitroglycerin plasma concentrations attained at 10, 20, 40, and 10 micrograms/min were 0.44 +/- 0.31, 1.32 +/- 0.71, 4.23 +/- 1.50 and 1.04 +/- 0.43 ng/ml, respectively.",Dose dependent pharmacokinetics of nitroglycerin after multiple intravenous infusions in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932639/),[ng] / [ml],0.44,141401,DB00727,Nitroglycerin
,3932639,plasma concentrations,"Steady-state nitroglycerin plasma concentrations attained at 10, 20, 40, and 10 micrograms/min were 0.44 +/- 0.31, 1.32 +/- 0.71, 4.23 +/- 1.50 and 1.04 +/- 0.43 ng/ml, respectively.",Dose dependent pharmacokinetics of nitroglycerin after multiple intravenous infusions in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932639/),[ng] / [ml],1.32,141402,DB00727,Nitroglycerin
,3932639,plasma concentrations,"Steady-state nitroglycerin plasma concentrations attained at 10, 20, 40, and 10 micrograms/min were 0.44 +/- 0.31, 1.32 +/- 0.71, 4.23 +/- 1.50 and 1.04 +/- 0.43 ng/ml, respectively.",Dose dependent pharmacokinetics of nitroglycerin after multiple intravenous infusions in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932639/),[ng] / [ml],4.23,141403,DB00727,Nitroglycerin
,3932639,plasma concentrations,"Steady-state nitroglycerin plasma concentrations attained at 10, 20, 40, and 10 micrograms/min were 0.44 +/- 0.31, 1.32 +/- 0.71, 4.23 +/- 1.50 and 1.04 +/- 0.43 ng/ml, respectively.",Dose dependent pharmacokinetics of nitroglycerin after multiple intravenous infusions in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932639/),[ng] / [ml],1.04,141404,DB00727,Nitroglycerin
,3932639,clearance,The clearance values (5.5 to 711/min) were very high and far exceed the maximum possible hepatic clearance suggesting that nitroglycerin is metabolized by organs other than liver.,Dose dependent pharmacokinetics of nitroglycerin after multiple intravenous infusions in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932639/),1/[min],5.5 to 711,141405,DB00727,Nitroglycerin
,3932639,Clearance,Clearance was not directly related to plasma concentrations but was found to decrease to a constant value (approximately 11 +/- 6 l/min) as nitroglycerin concentrations initially increased.,Dose dependent pharmacokinetics of nitroglycerin after multiple intravenous infusions in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932639/),[l] / [min],11,141406,DB00727,Nitroglycerin
,10764480,plasma levels,"Median maternal plasma levels 1 and 5 minutes after injection of 0.5 mg nitroglycerin were 80 and 3.2 ng/mL, respectively; median maternal plasma levels 1 and 5 minutes after injection of 0.25 mg nitroglycerin were 38 and 1.2 ng/mL, respectively.","Nitroglycerin application during cesarean delivery: plasma levels, fetal/maternal ratio of nitroglycerin, and effects in newborns. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10764480/),[ng] / [ml],80,142589,DB00727,Nitroglycerin
,10764480,plasma levels,"Median maternal plasma levels 1 and 5 minutes after injection of 0.5 mg nitroglycerin were 80 and 3.2 ng/mL, respectively; median maternal plasma levels 1 and 5 minutes after injection of 0.25 mg nitroglycerin were 38 and 1.2 ng/mL, respectively.","Nitroglycerin application during cesarean delivery: plasma levels, fetal/maternal ratio of nitroglycerin, and effects in newborns. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10764480/),[ng] / [ml],3.2,142590,DB00727,Nitroglycerin
,10764480,plasma levels,"Median maternal plasma levels 1 and 5 minutes after injection of 0.5 mg nitroglycerin were 80 and 3.2 ng/mL, respectively; median maternal plasma levels 1 and 5 minutes after injection of 0.25 mg nitroglycerin were 38 and 1.2 ng/mL, respectively.","Nitroglycerin application during cesarean delivery: plasma levels, fetal/maternal ratio of nitroglycerin, and effects in newborns. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10764480/),[ng] / [ml],38,142591,DB00727,Nitroglycerin
,10764480,plasma levels,"Median maternal plasma levels 1 and 5 minutes after injection of 0.5 mg nitroglycerin were 80 and 3.2 ng/mL, respectively; median maternal plasma levels 1 and 5 minutes after injection of 0.25 mg nitroglycerin were 38 and 1.2 ng/mL, respectively.","Nitroglycerin application during cesarean delivery: plasma levels, fetal/maternal ratio of nitroglycerin, and effects in newborns. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10764480/),[ng] / [ml],1.2,142592,DB00727,Nitroglycerin
,3922382,plasma concentrations,"The mean plasma concentrations for all subjects and all sampling times (nmol/l) +/- SE were 0.92 +/- 0.18, 0.80 +/- 0.12 and 0.97 +/- 0.18 for the commercial scale TTS and the 2 other systems, respectively.",Glycerol trinitrate (nitroglycerin) plasma concentrations achieved after application of transdermal therapeutic systems to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3922382/),[nM] / [l],0.92,148167,DB00727,Nitroglycerin
,3922382,plasma concentrations,"The mean plasma concentrations for all subjects and all sampling times (nmol/l) +/- SE were 0.92 +/- 0.18, 0.80 +/- 0.12 and 0.97 +/- 0.18 for the commercial scale TTS and the 2 other systems, respectively.",Glycerol trinitrate (nitroglycerin) plasma concentrations achieved after application of transdermal therapeutic systems to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3922382/),[nM] / [l],0.80,148168,DB00727,Nitroglycerin
,3922382,plasma concentrations,"The mean plasma concentrations for all subjects and all sampling times (nmol/l) +/- SE were 0.92 +/- 0.18, 0.80 +/- 0.12 and 0.97 +/- 0.18 for the commercial scale TTS and the 2 other systems, respectively.",Glycerol trinitrate (nitroglycerin) plasma concentrations achieved after application of transdermal therapeutic systems to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3922382/),[nM] / [l],0.97,148169,DB00727,Nitroglycerin
,3922382,delivery rate,The mean delivery rate of GTN calculated from the initial and residual contents of the TTS was 6.8 micrograms/min as a mean for the 3 systems.,Glycerol trinitrate (nitroglycerin) plasma concentrations achieved after application of transdermal therapeutic systems to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3922382/),[μg] / [min],6.8,148170,DB00727,Nitroglycerin
,6817769,Peak plasma GTN levels,2 Peak plasma GTN levels of 1.4 +/- 0.1 ng/ml were achieved at 3 min after sublingual administration (0.5 mg); 2.8 +/- 0.6 ng/ml and 2.5 +/- 0.3 ng/ml at 2 h and 4 h after Nitrocontin (6.4 mg) and Sustac (6.4 mg) respectively; 2.7 +/- 0.1 ng/ml and 2.5 +/- 0.2 ng/ml at 30 min after the cream (23 mg) and ointment (35 mg) respectively.,Pharmacokinetic studies of various preparations of glyceryl trinitrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6817769/),[ng] / [ml],1.4,148773,DB00727,Nitroglycerin
,6817769,Peak plasma GTN levels,2 Peak plasma GTN levels of 1.4 +/- 0.1 ng/ml were achieved at 3 min after sublingual administration (0.5 mg); 2.8 +/- 0.6 ng/ml and 2.5 +/- 0.3 ng/ml at 2 h and 4 h after Nitrocontin (6.4 mg) and Sustac (6.4 mg) respectively; 2.7 +/- 0.1 ng/ml and 2.5 +/- 0.2 ng/ml at 30 min after the cream (23 mg) and ointment (35 mg) respectively.,Pharmacokinetic studies of various preparations of glyceryl trinitrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6817769/),[ng] / [ml],2.8,148774,DB00727,Nitroglycerin
,6817769,Peak plasma GTN levels,2 Peak plasma GTN levels of 1.4 +/- 0.1 ng/ml were achieved at 3 min after sublingual administration (0.5 mg); 2.8 +/- 0.6 ng/ml and 2.5 +/- 0.3 ng/ml at 2 h and 4 h after Nitrocontin (6.4 mg) and Sustac (6.4 mg) respectively; 2.7 +/- 0.1 ng/ml and 2.5 +/- 0.2 ng/ml at 30 min after the cream (23 mg) and ointment (35 mg) respectively.,Pharmacokinetic studies of various preparations of glyceryl trinitrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6817769/),[ng] / [ml],2.5,148775,DB00727,Nitroglycerin
,6817769,Peak plasma GTN levels,2 Peak plasma GTN levels of 1.4 +/- 0.1 ng/ml were achieved at 3 min after sublingual administration (0.5 mg); 2.8 +/- 0.6 ng/ml and 2.5 +/- 0.3 ng/ml at 2 h and 4 h after Nitrocontin (6.4 mg) and Sustac (6.4 mg) respectively; 2.7 +/- 0.1 ng/ml and 2.5 +/- 0.2 ng/ml at 30 min after the cream (23 mg) and ointment (35 mg) respectively.,Pharmacokinetic studies of various preparations of glyceryl trinitrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6817769/),[ng] / [ml],2.7,148776,DB00727,Nitroglycerin
,6817769,Peak plasma GTN levels,2 Peak plasma GTN levels of 1.4 +/- 0.1 ng/ml were achieved at 3 min after sublingual administration (0.5 mg); 2.8 +/- 0.6 ng/ml and 2.5 +/- 0.3 ng/ml at 2 h and 4 h after Nitrocontin (6.4 mg) and Sustac (6.4 mg) respectively; 2.7 +/- 0.1 ng/ml and 2.5 +/- 0.2 ng/ml at 30 min after the cream (23 mg) and ointment (35 mg) respectively.,Pharmacokinetic studies of various preparations of glyceryl trinitrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6817769/),[ng] / [ml],2.5,148777,DB00727,Nitroglycerin
,6817769,times to reach half peak plasma GTN levels,"3 The mean times to reach half peak plasma GTN levels were 4.2 +/- 0.7 min after sublingual GTN, 6.5 +/- 0.9 h after Nitrocontin, 4.1 +/- 0.7 h after Sustac, 46.1 +/- 10.2 min after the ointment and 50.2 +/- 39.2 min after the cream.",Pharmacokinetic studies of various preparations of glyceryl trinitrate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6817769/),min,4.2,148778,DB00727,Nitroglycerin
,6817769,times to reach half peak plasma GTN levels,"3 The mean times to reach half peak plasma GTN levels were 4.2 +/- 0.7 min after sublingual GTN, 6.5 +/- 0.9 h after Nitrocontin, 4.1 +/- 0.7 h after Sustac, 46.1 +/- 10.2 min after the ointment and 50.2 +/- 39.2 min after the cream.",Pharmacokinetic studies of various preparations of glyceryl trinitrate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6817769/),h,6.5,148779,DB00727,Nitroglycerin
,6817769,times to reach half peak plasma GTN levels,"3 The mean times to reach half peak plasma GTN levels were 4.2 +/- 0.7 min after sublingual GTN, 6.5 +/- 0.9 h after Nitrocontin, 4.1 +/- 0.7 h after Sustac, 46.1 +/- 10.2 min after the ointment and 50.2 +/- 39.2 min after the cream.",Pharmacokinetic studies of various preparations of glyceryl trinitrate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6817769/),h,4.1,148780,DB00727,Nitroglycerin
,6817769,times to reach half peak plasma GTN levels,"3 The mean times to reach half peak plasma GTN levels were 4.2 +/- 0.7 min after sublingual GTN, 6.5 +/- 0.9 h after Nitrocontin, 4.1 +/- 0.7 h after Sustac, 46.1 +/- 10.2 min after the ointment and 50.2 +/- 39.2 min after the cream.",Pharmacokinetic studies of various preparations of glyceryl trinitrate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6817769/),min,46.1,148781,DB00727,Nitroglycerin
,6817769,times to reach half peak plasma GTN levels,"3 The mean times to reach half peak plasma GTN levels were 4.2 +/- 0.7 min after sublingual GTN, 6.5 +/- 0.9 h after Nitrocontin, 4.1 +/- 0.7 h after Sustac, 46.1 +/- 10.2 min after the ointment and 50.2 +/- 39.2 min after the cream.",Pharmacokinetic studies of various preparations of glyceryl trinitrate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6817769/),min,50.2,148782,DB00727,Nitroglycerin
,6817769,peak NO3 levels,"4 Plasma nitrate (NO3) levels were undetectable after sublingual administration; peak NO3 levels were 0.48 +/- 0.03 microgram/ml at 4 h after Nitrocontin, 0.45 +/- 0.02 microgram/ml at 6 h after Sustac, 0.68 +/- 0.04 microgram/ml at 6 h (end of study) after the ointment and 0.63 microgram/ml at 4 h after the cream.",Pharmacokinetic studies of various preparations of glyceryl trinitrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6817769/),[μg] / [ml],0.48,148783,DB00727,Nitroglycerin
,6817769,peak NO3 levels,"4 Plasma nitrate (NO3) levels were undetectable after sublingual administration; peak NO3 levels were 0.48 +/- 0.03 microgram/ml at 4 h after Nitrocontin, 0.45 +/- 0.02 microgram/ml at 6 h after Sustac, 0.68 +/- 0.04 microgram/ml at 6 h (end of study) after the ointment and 0.63 microgram/ml at 4 h after the cream.",Pharmacokinetic studies of various preparations of glyceryl trinitrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6817769/),[μg] / [ml],0.45,148784,DB00727,Nitroglycerin
,6817769,peak NO3 levels,"4 Plasma nitrate (NO3) levels were undetectable after sublingual administration; peak NO3 levels were 0.48 +/- 0.03 microgram/ml at 4 h after Nitrocontin, 0.45 +/- 0.02 microgram/ml at 6 h after Sustac, 0.68 +/- 0.04 microgram/ml at 6 h (end of study) after the ointment and 0.63 microgram/ml at 4 h after the cream.",Pharmacokinetic studies of various preparations of glyceryl trinitrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6817769/),[μg] / [ml],0.68,148785,DB00727,Nitroglycerin
,6817769,peak NO3 levels,"4 Plasma nitrate (NO3) levels were undetectable after sublingual administration; peak NO3 levels were 0.48 +/- 0.03 microgram/ml at 4 h after Nitrocontin, 0.45 +/- 0.02 microgram/ml at 6 h after Sustac, 0.68 +/- 0.04 microgram/ml at 6 h (end of study) after the ointment and 0.63 microgram/ml at 4 h after the cream.",Pharmacokinetic studies of various preparations of glyceryl trinitrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6817769/),[μg] / [ml],0.63,148786,DB00727,Nitroglycerin
,6817769,peak NO2 levels,"5 Plasma nitrite (NO2) was undetectable after sublingual GTN and peak NO2 levels were 0.48 +/- 0.04 microgram/ml at 2 h after Nitrocontin, 0.48 +/- 0.02 microgram/ml at 2 h after Sustac, 0.69 +/- 0.02 microgram/ml at 1 h after the ointment and 0.64 +/- 0.02 microgram/ml at 1 h after the cream.",Pharmacokinetic studies of various preparations of glyceryl trinitrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6817769/),[μg] / [ml],0.48,148787,DB00727,Nitroglycerin
,6817769,peak NO2 levels,"5 Plasma nitrite (NO2) was undetectable after sublingual GTN and peak NO2 levels were 0.48 +/- 0.04 microgram/ml at 2 h after Nitrocontin, 0.48 +/- 0.02 microgram/ml at 2 h after Sustac, 0.69 +/- 0.02 microgram/ml at 1 h after the ointment and 0.64 +/- 0.02 microgram/ml at 1 h after the cream.",Pharmacokinetic studies of various preparations of glyceryl trinitrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6817769/),[μg] / [ml],0.48,148788,DB00727,Nitroglycerin
,6817769,peak NO2 levels,"5 Plasma nitrite (NO2) was undetectable after sublingual GTN and peak NO2 levels were 0.48 +/- 0.04 microgram/ml at 2 h after Nitrocontin, 0.48 +/- 0.02 microgram/ml at 2 h after Sustac, 0.69 +/- 0.02 microgram/ml at 1 h after the ointment and 0.64 +/- 0.02 microgram/ml at 1 h after the cream.",Pharmacokinetic studies of various preparations of glyceryl trinitrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6817769/),[μg] / [ml],0.69,148789,DB00727,Nitroglycerin
,6817769,peak NO2 levels,"5 Plasma nitrite (NO2) was undetectable after sublingual GTN and peak NO2 levels were 0.48 +/- 0.04 microgram/ml at 2 h after Nitrocontin, 0.48 +/- 0.02 microgram/ml at 2 h after Sustac, 0.69 +/- 0.02 microgram/ml at 1 h after the ointment and 0.64 +/- 0.02 microgram/ml at 1 h after the cream.",Pharmacokinetic studies of various preparations of glyceryl trinitrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6817769/),[μg] / [ml],0.64,148790,DB00727,Nitroglycerin
,3084758,AUC,"The mean AUC for preparation A, 159 +/- 66 h X pg/mL, was 2.7 times greater than for B, 59 +/- 33 h X pg/mL.",Relative bioavailability of two spray formulations of nitroglycerin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3084758/),[h·pg] / [ml],159,150230,DB00727,Nitroglycerin
,3084758,AUC,"The mean AUC for preparation A, 159 +/- 66 h X pg/mL, was 2.7 times greater than for B, 59 +/- 33 h X pg/mL.",Relative bioavailability of two spray formulations of nitroglycerin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3084758/),[h·pg] / [ml],59,150231,DB00727,Nitroglycerin
,3084758,maximum plasma concentration,The mean maximum plasma concentration for A was 1387 +/- 620 pg/mL which was 4.1 times greater than the mean maximum plasma concentration for preparation B (340 +/- 234 pg/mL).,Relative bioavailability of two spray formulations of nitroglycerin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3084758/),[pg] / [ml],1387,150232,DB00727,Nitroglycerin
,3084758,maximum plasma concentration,The mean maximum plasma concentration for A was 1387 +/- 620 pg/mL which was 4.1 times greater than the mean maximum plasma concentration for preparation B (340 +/- 234 pg/mL).,Relative bioavailability of two spray formulations of nitroglycerin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3084758/),[pg] / [ml],340,150233,DB00727,Nitroglycerin
,3084758,time of maximum plasma concentration,"The time of maximum plasma concentration also occurred earlier for preparation A versus B, 4.3 +/- 1.6 versus 8.3 +/- 2.0 min, respectively.",Relative bioavailability of two spray formulations of nitroglycerin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3084758/),min,4.3,150234,DB00727,Nitroglycerin
,3084758,time of maximum plasma concentration,"The time of maximum plasma concentration also occurred earlier for preparation A versus B, 4.3 +/- 1.6 versus 8.3 +/- 2.0 min, respectively.",Relative bioavailability of two spray formulations of nitroglycerin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3084758/),min,8.3,150235,DB00727,Nitroglycerin
,9853974,k(f1),"Some of the mean PK parameters estimates and their interindividual variability (CV%) were the percentage of the delivered GTN dose reaching the systemic circulation released by a first-order process A, 53% (44); the 1,2-GDN and 1,3-GDN formation rate constants, k(f1)9 h(-1) (67) and k(f2) 0.5 h(-1) (38), respectively; the metabolite elimination rate constant, k(m) 1 h(-1) (27); GTN, 1,2-GDN, and 1,3-GDN volumes of distribution (Vc/F 6 L [45]), V2/F 78 L [51]), and V3/F 29 L [40]), respectively).",Population pharmacokinetics of nitroglycerin and of its two metabolites after a single 24-hour application of a nitroglycerin transdermal matrix delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853974/),1/[h],9,156322,DB00727,Nitroglycerin
,9853974,k(f2),"Some of the mean PK parameters estimates and their interindividual variability (CV%) were the percentage of the delivered GTN dose reaching the systemic circulation released by a first-order process A, 53% (44); the 1,2-GDN and 1,3-GDN formation rate constants, k(f1)9 h(-1) (67) and k(f2) 0.5 h(-1) (38), respectively; the metabolite elimination rate constant, k(m) 1 h(-1) (27); GTN, 1,2-GDN, and 1,3-GDN volumes of distribution (Vc/F 6 L [45]), V2/F 78 L [51]), and V3/F 29 L [40]), respectively).",Population pharmacokinetics of nitroglycerin and of its two metabolites after a single 24-hour application of a nitroglycerin transdermal matrix delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853974/),1/[h],0.5,156323,DB00727,Nitroglycerin
,9853974,k(m),"Some of the mean PK parameters estimates and their interindividual variability (CV%) were the percentage of the delivered GTN dose reaching the systemic circulation released by a first-order process A, 53% (44); the 1,2-GDN and 1,3-GDN formation rate constants, k(f1)9 h(-1) (67) and k(f2) 0.5 h(-1) (38), respectively; the metabolite elimination rate constant, k(m) 1 h(-1) (27); GTN, 1,2-GDN, and 1,3-GDN volumes of distribution (Vc/F 6 L [45]), V2/F 78 L [51]), and V3/F 29 L [40]), respectively).",Population pharmacokinetics of nitroglycerin and of its two metabolites after a single 24-hour application of a nitroglycerin transdermal matrix delivery system. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853974/),1/[h],1,156324,DB00727,Nitroglycerin
,9853974,volumes of distribution (Vc/F,"Some of the mean PK parameters estimates and their interindividual variability (CV%) were the percentage of the delivered GTN dose reaching the systemic circulation released by a first-order process A, 53% (44); the 1,2-GDN and 1,3-GDN formation rate constants, k(f1)9 h(-1) (67) and k(f2) 0.5 h(-1) (38), respectively; the metabolite elimination rate constant, k(m) 1 h(-1) (27); GTN, 1,2-GDN, and 1,3-GDN volumes of distribution (Vc/F 6 L [45]), V2/F 78 L [51]), and V3/F 29 L [40]), respectively).",Population pharmacokinetics of nitroglycerin and of its two metabolites after a single 24-hour application of a nitroglycerin transdermal matrix delivery system. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853974/),l,6,156325,DB00727,Nitroglycerin
,9853974,V2/F,"Some of the mean PK parameters estimates and their interindividual variability (CV%) were the percentage of the delivered GTN dose reaching the systemic circulation released by a first-order process A, 53% (44); the 1,2-GDN and 1,3-GDN formation rate constants, k(f1)9 h(-1) (67) and k(f2) 0.5 h(-1) (38), respectively; the metabolite elimination rate constant, k(m) 1 h(-1) (27); GTN, 1,2-GDN, and 1,3-GDN volumes of distribution (Vc/F 6 L [45]), V2/F 78 L [51]), and V3/F 29 L [40]), respectively).",Population pharmacokinetics of nitroglycerin and of its two metabolites after a single 24-hour application of a nitroglycerin transdermal matrix delivery system. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853974/),l,78,156326,DB00727,Nitroglycerin
,9853974,V3/F,"Some of the mean PK parameters estimates and their interindividual variability (CV%) were the percentage of the delivered GTN dose reaching the systemic circulation released by a first-order process A, 53% (44); the 1,2-GDN and 1,3-GDN formation rate constants, k(f1)9 h(-1) (67) and k(f2) 0.5 h(-1) (38), respectively; the metabolite elimination rate constant, k(m) 1 h(-1) (27); GTN, 1,2-GDN, and 1,3-GDN volumes of distribution (Vc/F 6 L [45]), V2/F 78 L [51]), and V3/F 29 L [40]), respectively).",Population pharmacokinetics of nitroglycerin and of its two metabolites after a single 24-hour application of a nitroglycerin transdermal matrix delivery system. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853974/),l,29,156327,DB00727,Nitroglycerin
,9853974,elimination half-lives (t1/2,"Mean calculated elimination half-lives (t1/2+/-standard deviation [SD]) for GTN and the GDN metabolites were 7+/-4 minutes and 33+/-7 minutes, respectively.",Population pharmacokinetics of nitroglycerin and of its two metabolites after a single 24-hour application of a nitroglycerin transdermal matrix delivery system. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853974/),min,7,156328,DB00727,Nitroglycerin
,9853974,elimination half-lives (t1/2,"Mean calculated elimination half-lives (t1/2+/-standard deviation [SD]) for GTN and the GDN metabolites were 7+/-4 minutes and 33+/-7 minutes, respectively.",Population pharmacokinetics of nitroglycerin and of its two metabolites after a single 24-hour application of a nitroglycerin transdermal matrix delivery system. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853974/),min,33,156329,DB00727,Nitroglycerin
,17522570,maximum tolerated,"The median maximum tolerated NTG dose (range) was 80 (0-160) microg/min for sildenafil vs. 160 (20-160) microg/min for placebo (adjusted mean +/- se, 77 +/- 7 vs. 127 +/- 7; p < .0001; analysis of variance), and NTG 160 microg/min was tolerated by eight (25%) and 19 (59%) men, respectively (p = .0008).","Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17522570/),[μg] / [min],80,158142,DB00727,Nitroglycerin
,17522570,maximum tolerated,"The median maximum tolerated NTG dose (range) was 80 (0-160) microg/min for sildenafil vs. 160 (20-160) microg/min for placebo (adjusted mean +/- se, 77 +/- 7 vs. 127 +/- 7; p < .0001; analysis of variance), and NTG 160 microg/min was tolerated by eight (25%) and 19 (59%) men, respectively (p = .0008).","Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17522570/),[μg] / [min],160,158143,DB00727,Nitroglycerin
,17522570,maximum tolerated,"The median maximum tolerated NTG dose (range) was 80 (0-160) microg/min for sildenafil vs. 160 (20-160) microg/min for placebo (adjusted mean +/- se, 77 +/- 7 vs. 127 +/- 7; p < .0001; analysis of variance), and NTG 160 microg/min was tolerated by eight (25%) and 19 (59%) men, respectively (p = .0008).","Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17522570/),,77,158144,DB00727,Nitroglycerin
,17522570,maximum tolerated,"The median maximum tolerated NTG dose (range) was 80 (0-160) microg/min for sildenafil vs. 160 (20-160) microg/min for placebo (adjusted mean +/- se, 77 +/- 7 vs. 127 +/- 7; p < .0001; analysis of variance), and NTG 160 microg/min was tolerated by eight (25%) and 19 (59%) men, respectively (p = .0008).","Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17522570/),,127,158145,DB00727,Nitroglycerin
,3935852,elimination half-life,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),h,1.35,158315,DB00727,Nitroglycerin
,3935852,elimination half-life,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),h,1.10,158316,DB00727,Nitroglycerin
,3935852,elimination half-life,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),h,1.09,158317,DB00727,Nitroglycerin
,3935852,total area under the curve,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),[ng] / [h·ml],42,158318,DB00727,Nitroglycerin
,3935852,total area under the curve,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),[ng] / [h·ml],38,158319,DB00727,Nitroglycerin
,3935852,oral clearance,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),[l] / [min],6.6,158320,DB00727,Nitroglycerin
,3935852,oral clearance,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),[l] / [min],7.2,158321,DB00727,Nitroglycerin
,3935852,oral clearance,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),[l] / [min],6.4,158322,DB00727,Nitroglycerin
,6196556,apparent plasma elimination half-life,The apparent plasma elimination half-life was 4.4 +/- 0.4 h.,Clinical pharmacology and pharmacokinetics of prizidilol in hypertensive patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6196556/),h,4.4,159332,DB00727,Nitroglycerin
,3743616,peak malotilate plasma concentration,After a single dose of 500 mg malotilate p.o. peak malotilate plasma concentration measured by GC-MS was 35 times higher in patients (median 0.70 micrograms/ml) than in controls (median 0.019 micrograms/ml).,Treatment of liver disease with malotilate. A pharmacokinetic and pharmacodynamic phase II study in cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3743616/),[μg] / [ml],0.70,161097,DB00727,Nitroglycerin
,3743616,peak malotilate plasma concentration,After a single dose of 500 mg malotilate p.o. peak malotilate plasma concentration measured by GC-MS was 35 times higher in patients (median 0.70 micrograms/ml) than in controls (median 0.019 micrograms/ml).,Treatment of liver disease with malotilate. A pharmacokinetic and pharmacodynamic phase II study in cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3743616/),[μg] / [ml],0.019,161098,DB00727,Nitroglycerin
,3743616,apparent oral clearance,The median apparent oral clearance was approximately 50 times lower in cirrhotics (median 2.21/min) than in healthy volunteers (1181/min).,Treatment of liver disease with malotilate. A pharmacokinetic and pharmacodynamic phase II study in cirrhosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3743616/),1/[min],2.21,161099,DB00727,Nitroglycerin
,3743616,apparent oral clearance,The median apparent oral clearance was approximately 50 times lower in cirrhotics (median 2.21/min) than in healthy volunteers (1181/min).,Treatment of liver disease with malotilate. A pharmacokinetic and pharmacodynamic phase II study in cirrhosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3743616/),1/[min],1181,161100,DB00727,Nitroglycerin
,19703372,t(max),"Following intranasal delivery, median t(max) was 20 min with both doses compared with 10 min after the subcutaneous dose.",Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19703372/),min,20,165421,DB00727,Nitroglycerin
,19703372,t(max),"Following intranasal delivery, median t(max) was 20 min with both doses compared with 10 min after the subcutaneous dose.",Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19703372/),min,10,165422,DB00727,Nitroglycerin
,19703372,C(max),"Mean +/- SD values for C(max) were 96 +/- 25, 11 +/- 7 and 16 +/- 6 ng/ml for subcutaneous, intranasal 10 mg and intranasal 20 mg formulations, respectively.",Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19703372/),[ng] / [ml],96,165423,DB00727,Nitroglycerin
,19703372,C(max),"Mean +/- SD values for C(max) were 96 +/- 25, 11 +/- 7 and 16 +/- 6 ng/ml for subcutaneous, intranasal 10 mg and intranasal 20 mg formulations, respectively.",Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19703372/),[ng] / [ml],11,165424,DB00727,Nitroglycerin
,19703372,C(max),"Mean +/- SD values for C(max) were 96 +/- 25, 11 +/- 7 and 16 +/- 6 ng/ml for subcutaneous, intranasal 10 mg and intranasal 20 mg formulations, respectively.",Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19703372/),[ng] / [ml],16,165425,DB00727,Nitroglycerin
,3100600,peak plasma concentration,Two patients had a minimal hemodynamic response and a peak plasma concentration of 1 ng/ml.,Pharmacokinetic-hemodynamic studies of transdermal nitroglycerin in congestive heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3100600/),[ng] / [ml],1,165486,DB00727,Nitroglycerin
,3100600,highest plasma concentration,The highest plasma concentration achieved in these patients was 2 ng/ml and there was no relation between dose administered and plasma concentration achieved.,Pharmacokinetic-hemodynamic studies of transdermal nitroglycerin in congestive heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3100600/),[ng] / [ml],2,165487,DB00727,Nitroglycerin
,9652881,Plasma concentrations,Plasma concentrations of nitroglycerin increased from 223 pg/mL to 558 and 803 pg/mL on day 1 and amounted to 205 ng/mL at 2.5 hours on day 2.,Increasing nitroglycerin release from patches enables circumvention of early nitrate tolerance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9652881/),[pg] / [ml],223,169129,DB00727,Nitroglycerin
,9652881,Plasma concentrations,Plasma concentrations of nitroglycerin increased from 223 pg/mL to 558 and 803 pg/mL on day 1 and amounted to 205 ng/mL at 2.5 hours on day 2.,Increasing nitroglycerin release from patches enables circumvention of early nitrate tolerance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9652881/),p,55,169130,DB00727,Nitroglycerin
,9652881,Plasma concentrations,Plasma concentrations of nitroglycerin increased from 223 pg/mL to 558 and 803 pg/mL on day 1 and amounted to 205 ng/mL at 2.5 hours on day 2.,Increasing nitroglycerin release from patches enables circumvention of early nitrate tolerance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9652881/),p,80,169131,DB00727,Nitroglycerin
,9652881,Plasma concentrations,Plasma concentrations of nitroglycerin increased from 223 pg/mL to 558 and 803 pg/mL on day 1 and amounted to 205 ng/mL at 2.5 hours on day 2.,Increasing nitroglycerin release from patches enables circumvention of early nitrate tolerance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9652881/),[ng] / [ml],205,169132,DB00727,Nitroglycerin
,16259771,total area under the plasma concentration-time curve from time zero to time infinity (AUC(inf)),"After simultaneous intravenous administration, the total area under the plasma concentration-time curve from time zero to time infinity (AUC(inf)) of DA-8159 (746 vs 457 microg min mL(-1)) was found to be significantly greater than with DA-8159 alone.","Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16259771/),[min·μg] / [ml],746,171951,DB00727,Nitroglycerin
,16259771,total area under the plasma concentration-time curve from time zero to time infinity (AUC(inf)),"After simultaneous intravenous administration, the total area under the plasma concentration-time curve from time zero to time infinity (AUC(inf)) of DA-8159 (746 vs 457 microg min mL(-1)) was found to be significantly greater than with DA-8159 alone.","Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16259771/),[min·μg] / [ml],457,171952,DB00727,Nitroglycerin
,16259771,total body clearance (CL),"Also, after simultaneous intravenous administration total body clearance (CL) (40.2 vs 65.6 mL min(-1) kg(-1)), renal clearance (CL(R)) (1.65 vs 5.11 mL min(-1) kg(-1)), and nonrenal clearance (CL(NR)) (38.3 vs 60.2 mL min(-1) kg(-1)) of DA-8159 were significantly slower compared with DA-8159 alone.","Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16259771/),[ml] / [kg·min],40.2,171953,DB00727,Nitroglycerin
,16259771,total body clearance (CL),"Also, after simultaneous intravenous administration total body clearance (CL) (40.2 vs 65.6 mL min(-1) kg(-1)), renal clearance (CL(R)) (1.65 vs 5.11 mL min(-1) kg(-1)), and nonrenal clearance (CL(NR)) (38.3 vs 60.2 mL min(-1) kg(-1)) of DA-8159 were significantly slower compared with DA-8159 alone.","Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16259771/),[ml] / [kg·min],65.6,171954,DB00727,Nitroglycerin
,16259771,renal clearance (CL(R)),"Also, after simultaneous intravenous administration total body clearance (CL) (40.2 vs 65.6 mL min(-1) kg(-1)), renal clearance (CL(R)) (1.65 vs 5.11 mL min(-1) kg(-1)), and nonrenal clearance (CL(NR)) (38.3 vs 60.2 mL min(-1) kg(-1)) of DA-8159 were significantly slower compared with DA-8159 alone.","Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16259771/),[ml] / [kg·min],1.65,171955,DB00727,Nitroglycerin
,16259771,renal clearance (CL(R)),"Also, after simultaneous intravenous administration total body clearance (CL) (40.2 vs 65.6 mL min(-1) kg(-1)), renal clearance (CL(R)) (1.65 vs 5.11 mL min(-1) kg(-1)), and nonrenal clearance (CL(NR)) (38.3 vs 60.2 mL min(-1) kg(-1)) of DA-8159 were significantly slower compared with DA-8159 alone.","Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16259771/),[ml] / [kg·min],5.11,171956,DB00727,Nitroglycerin
,16259771,nonrenal clearance (CL(NR)),"Also, after simultaneous intravenous administration total body clearance (CL) (40.2 vs 65.6 mL min(-1) kg(-1)), renal clearance (CL(R)) (1.65 vs 5.11 mL min(-1) kg(-1)), and nonrenal clearance (CL(NR)) (38.3 vs 60.2 mL min(-1) kg(-1)) of DA-8159 were significantly slower compared with DA-8159 alone.","Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16259771/),[ml] / [kg·min],38.3,171957,DB00727,Nitroglycerin
,16259771,nonrenal clearance (CL(NR)),"Also, after simultaneous intravenous administration total body clearance (CL) (40.2 vs 65.6 mL min(-1) kg(-1)), renal clearance (CL(R)) (1.65 vs 5.11 mL min(-1) kg(-1)), and nonrenal clearance (CL(NR)) (38.3 vs 60.2 mL min(-1) kg(-1)) of DA-8159 were significantly slower compared with DA-8159 alone.","Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16259771/),[ml] / [kg·min],60.2,171958,DB00727,Nitroglycerin
,16259771,AUC(inf),"After the simultaneous intravenous administration of nitroglycerin and DA-8159, the AUC(inf) of nitroglycerin was significantly smaller (635 vs 960 microg min mL(-1)), which could have been due to the cardiac output-dependent CL of nitroglycerin.","Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16259771/),[min·μg] / [ml],635,171959,DB00727,Nitroglycerin
,16259771,AUC(inf),"After the simultaneous intravenous administration of nitroglycerin and DA-8159, the AUC(inf) of nitroglycerin was significantly smaller (635 vs 960 microg min mL(-1)), which could have been due to the cardiac output-dependent CL of nitroglycerin.","Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16259771/),[min·μg] / [ml],960,171960,DB00727,Nitroglycerin
,3147725,Cmax,"The mean GTN Cmax values of the three solution doses were 0.28, 0.78, and 0.42 ng ml-1 in ascending dosage.",Pharmacokinetics of nitroglycerin and metabolites in humans following oral dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3147725/),[ng] / [ml],0.28,172832,DB00727,Nitroglycerin
,3147725,Cmax,"The mean GTN Cmax values of the three solution doses were 0.28, 0.78, and 0.42 ng ml-1 in ascending dosage.",Pharmacokinetics of nitroglycerin and metabolites in humans following oral dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3147725/),[ng] / [ml],0.78,172833,DB00727,Nitroglycerin
,3147725,Cmax,"The mean GTN Cmax values of the three solution doses were 0.28, 0.78, and 0.42 ng ml-1 in ascending dosage.",Pharmacokinetics of nitroglycerin and metabolites in humans following oral dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3147725/),[ng] / [ml],0.42,172834,DB00727,Nitroglycerin
,3147725,tmax,"The erratic nature of GTN plasma profiles prevented meaningful pharmacokinetic analysis, although tmax was consistently 5 min.",Pharmacokinetics of nitroglycerin and metabolites in humans following oral dosing. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3147725/),min,5,172835,DB00727,Nitroglycerin
,3147725,Terminal half-lives,Terminal half-lives for both GDNs were approximately 50 min in all three doses.,Pharmacokinetics of nitroglycerin and metabolites in humans following oral dosing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3147725/),min,50,172836,DB00727,Nitroglycerin
,3105569,apparent volume of,"The apparent volume of G-1-N distribution was 601 corresponding to 0.761 kg-1 body weight, on average.",Glyceryl-1-nitrate pharmacokinetics in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3105569/),,601,174317,DB00727,Nitroglycerin
,3105569,clearance,Mean intravenous clearance was 283 ml min-1 or 3.61 ml min-1 kg-1.,Glyceryl-1-nitrate pharmacokinetics in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3105569/),[ml] / [min],283,174318,DB00727,Nitroglycerin
,3105569,clearance,Mean intravenous clearance was 283 ml min-1 or 3.61 ml min-1 kg-1.,Glyceryl-1-nitrate pharmacokinetics in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3105569/),[ml] / [kg·min],3.61,174319,DB00727,Nitroglycerin
,3105569,elimination half-lives,The average of elimination half-lives were 2.50 +/- 0.36 (s.d.) h after the intravenous and 2.54 +/- 0.40 (s.d.) h after the oral dose.,Glyceryl-1-nitrate pharmacokinetics in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3105569/),h,2.50,174320,DB00727,Nitroglycerin
,3105569,elimination half-lives,The average of elimination half-lives were 2.50 +/- 0.36 (s.d.) h after the intravenous and 2.54 +/- 0.40 (s.d.) h after the oral dose.,Glyceryl-1-nitrate pharmacokinetics in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3105569/),h,2.54,174321,DB00727,Nitroglycerin
,3105569,oral bioavailability,The oral bioavailability on the basis of areas under the curve amounted to 88.6% on the average.,Glyceryl-1-nitrate pharmacokinetics in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3105569/),%,88.6,174322,DB00727,Nitroglycerin
,6435484,plasma concentrations,Mean plasma concentrations for both treatments ranged from 10-18 pg/ml-cm2.,Nitroglycerin concentration in plasma: comparison between transdermal therapeutic system and ointment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6435484/),[pg] / [ml-cm2],10-18,174696,DB00727,Nitroglycerin
,6435484,normalized areas under the curves,"The normalized areas under the curves--353 and 410 pg/hr/ml-cm2, respectively--did not differ significantly.",Nitroglycerin concentration in plasma: comparison between transdermal therapeutic system and ointment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6435484/),[pg] / [h·ml-cm2],353,174697,DB00727,Nitroglycerin
,6435484,normalized areas under the curves,"The normalized areas under the curves--353 and 410 pg/hr/ml-cm2, respectively--did not differ significantly.",Nitroglycerin concentration in plasma: comparison between transdermal therapeutic system and ointment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6435484/),[pg] / [h·ml-cm2],410,174698,DB00727,Nitroglycerin
,6814785,total peripheral resistance,"Nitroglycerin infusion produced no change in heart rate, a reduction in mean arterial pressure from 90 +/- 21 (+/- SD) to 83 +/- 17 mm Hg (p less than 0.001), a fall in total peripheral resistance from 24.3 +/- 10.8 to 20.8 +/- 7.0 units (p less than 0.02), and a substantial reduction in both pulmonary capillary wedge pressure (from 27 +/- 6 to 20 +/- 6 mm Hg, p less than 0.001) and right atrial pressure (from 12 +/- 4 to 8 +/- 4 mm Hg, p less than 0.001).",Arterial-venous nitroglycerin gradient during intravenous infusion in man. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6814785/),units,24.3,184159,DB00727,Nitroglycerin
,6814785,total peripheral resistance,"Nitroglycerin infusion produced no change in heart rate, a reduction in mean arterial pressure from 90 +/- 21 (+/- SD) to 83 +/- 17 mm Hg (p less than 0.001), a fall in total peripheral resistance from 24.3 +/- 10.8 to 20.8 +/- 7.0 units (p less than 0.02), and a substantial reduction in both pulmonary capillary wedge pressure (from 27 +/- 6 to 20 +/- 6 mm Hg, p less than 0.001) and right atrial pressure (from 12 +/- 4 to 8 +/- 4 mm Hg, p less than 0.001).",Arterial-venous nitroglycerin gradient during intravenous infusion in man. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6814785/),units,20.8,184160,DB00727,Nitroglycerin
,6814785,extraction,There was a 17.4 +/- 19.1% extraction of GTN across the pulmonary vascular bed and a 60.8 +/- 27.2% extraction across the arterial-venous bed (p less than 0.001).,Arterial-venous nitroglycerin gradient during intravenous infusion in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6814785/),%,17.4,184161,DB00727,Nitroglycerin
,3150048,recoveries,"Using methyl t-butyl ether as extraction solvent and o-chloronitrobenzene as internal standard, recoveries from plasma spiked at levels greater than 10 ng/ml approximated 35% for the 1-monometabolite, 40% for the 2-monometabolite, and greater than 90% for all others.",Capillary gas chromatographic (GC) analysis of nitroglycerin and its denitration products in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3150048/),%,35,184776,DB00727,Nitroglycerin
,3150048,recoveries,"Using methyl t-butyl ether as extraction solvent and o-chloronitrobenzene as internal standard, recoveries from plasma spiked at levels greater than 10 ng/ml approximated 35% for the 1-monometabolite, 40% for the 2-monometabolite, and greater than 90% for all others.",Capillary gas chromatographic (GC) analysis of nitroglycerin and its denitration products in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3150048/),%,40,184777,DB00727,Nitroglycerin
greater,3150048,recoveries,"Using methyl t-butyl ether as extraction solvent and o-chloronitrobenzene as internal standard, recoveries from plasma spiked at levels greater than 10 ng/ml approximated 35% for the 1-monometabolite, 40% for the 2-monometabolite, and greater than 90% for all others.",Capillary gas chromatographic (GC) analysis of nitroglycerin and its denitration products in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3150048/),%,90,184778,DB00727,Nitroglycerin
,11050694,release rate,"The three strengths coded in this paper EPI-5, EPI-10 and EPI-15 have a nominal release rate of GTN of 5, 10 and 15 mg, respectively, in 24 h.",Plasma levels of glyceryl trinitrate and dinitrates during application of three strengths of a new glyceryl trinitrate transdermal patch. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050694/),mg,5,187152,DB00727,Nitroglycerin
,11050694,release rate,"The three strengths coded in this paper EPI-5, EPI-10 and EPI-15 have a nominal release rate of GTN of 5, 10 and 15 mg, respectively, in 24 h.",Plasma levels of glyceryl trinitrate and dinitrates during application of three strengths of a new glyceryl trinitrate transdermal patch. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050694/),mg,10,187153,DB00727,Nitroglycerin
,11050694,release rate,"The three strengths coded in this paper EPI-5, EPI-10 and EPI-15 have a nominal release rate of GTN of 5, 10 and 15 mg, respectively, in 24 h.",Plasma levels of glyceryl trinitrate and dinitrates during application of three strengths of a new glyceryl trinitrate transdermal patch. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050694/),mg,15,187154,DB00727,Nitroglycerin
,3100313,concentration-time curves,"The mean concentration-time curves peaked 40 min after administration of tablets at 144 ng/ml (10 mg), 308 ng/ml (20 mg) and 573 ng/ml (40 mg).",Pharmacokinetics of oral glycerol-1-nitrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3100313/),[ng] / [ml],144,193211,DB00727,Nitroglycerin
,3100313,concentration-time curves,"The mean concentration-time curves peaked 40 min after administration of tablets at 144 ng/ml (10 mg), 308 ng/ml (20 mg) and 573 ng/ml (40 mg).",Pharmacokinetics of oral glycerol-1-nitrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3100313/),[ng] / [ml],308,193212,DB00727,Nitroglycerin
,3100313,concentration-time curves,"The mean concentration-time curves peaked 40 min after administration of tablets at 144 ng/ml (10 mg), 308 ng/ml (20 mg) and 573 ng/ml (40 mg).",Pharmacokinetics of oral glycerol-1-nitrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3100313/),[ng] / [ml],573,193213,DB00727,Nitroglycerin
,3100313,peak,After the drops the peak of 324 ng/ml occurred at 1 h.,Pharmacokinetics of oral glycerol-1-nitrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3100313/),[ng] / [ml],324,193214,DB00727,Nitroglycerin
,3100313,bioavailability,The bioavailability of the 20 mg tablet relative to the 20 mg drops was 98.6% in terms of area under the curve.,Pharmacokinetics of oral glycerol-1-nitrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3100313/),%,98.6,193215,DB00727,Nitroglycerin
,3100313,apparent half-life,The mean apparent half-life of G-1-N elimination from plasma was 2.69 +/- 0.67 h (n = 46).,Pharmacokinetics of oral glycerol-1-nitrate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3100313/),h,2.69,193216,DB00727,Nitroglycerin
,3100313,mean residence time,The mean residence time of G-1-N in the body was 4.65 h compared to 0.28 h for glycerol trinitrate after buccal administration.,Pharmacokinetics of oral glycerol-1-nitrate. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3100313/),h,4.65,193217,DB00727,Nitroglycerin
,3100313,mean residence time,The mean residence time of G-1-N in the body was 4.65 h compared to 0.28 h for glycerol trinitrate after buccal administration.,Pharmacokinetics of oral glycerol-1-nitrate. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3100313/),h,0.28,193218,DB00727,Nitroglycerin
more,8010999,half-life of elimination,The differences in dogs are probably explained by enantiospecific pharmacokinetics: (d) G-1-N had higher plasma levels and showed a longer half-life of elimination than (l) G-1-N (more than 5 h versus 2.7 h).,Pharmacological comparison of the stereoisomers of glyceryl-1-nitrate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010999/),h,5,199176,DB00727,Nitroglycerin
,8010999,half-life of elimination,The differences in dogs are probably explained by enantiospecific pharmacokinetics: (d) G-1-N had higher plasma levels and showed a longer half-life of elimination than (l) G-1-N (more than 5 h versus 2.7 h).,Pharmacological comparison of the stereoisomers of glyceryl-1-nitrate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010999/),h,2.7,199177,DB00727,Nitroglycerin
,11835062,total amount of NTG transdermally absorbed (AUC x CL),The total amount of NTG transdermally absorbed (AUC x CL) during a 22-h application for the experimental system was not statistically different from that for the commercial system (9.7 plus minus 3.3 versus 8.1 plus minus 2.6 mg; p = 0.41).,Application of a Stable Isotope Technique for the Bioequivalency Study of Two Transdermal Nitroglycerin Systems. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11835062/),mg,9.7,199925,DB00727,Nitroglycerin
,11835062,total amount of NTG transdermally absorbed (AUC x CL),The total amount of NTG transdermally absorbed (AUC x CL) during a 22-h application for the experimental system was not statistically different from that for the commercial system (9.7 plus minus 3.3 versus 8.1 plus minus 2.6 mg; p = 0.41).,Application of a Stable Isotope Technique for the Bioequivalency Study of Two Transdermal Nitroglycerin Systems. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11835062/),mg,8.1,199926,DB00727,Nitroglycerin
,11835062,peak concentration,The peak concentration values were 0.52 plus minus 0.21 mg h(minus sign1) at 1 h for the experimental system and 0.41 plus minus 0.15 mg h(minus sign1) at 2 h for commercial systems.,Application of a Stable Isotope Technique for the Bioequivalency Study of Two Transdermal Nitroglycerin Systems. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11835062/),h·mg,0.52,199927,DB00727,Nitroglycerin
,11835062,peak concentration,The peak concentration values were 0.52 plus minus 0.21 mg h(minus sign1) at 1 h for the experimental system and 0.41 plus minus 0.15 mg h(minus sign1) at 2 h for commercial systems.,Application of a Stable Isotope Technique for the Bioequivalency Study of Two Transdermal Nitroglycerin Systems. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11835062/),h·mg,0.41,199928,DB00727,Nitroglycerin
,3092486,terminal half-life,"The terminal half-life is 2-6 minutes, and clearance about 30 l/min.",[Pharmacokinetics of glycerol trinitrate]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3092486/),min,2-6,212743,DB00727,Nitroglycerin
,3092486,clearance,"The terminal half-life is 2-6 minutes, and clearance about 30 l/min.",[Pharmacokinetics of glycerol trinitrate]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3092486/),[l] / [min],30,212744,DB00727,Nitroglycerin
,6798193,highest observed concentrations,"Plasma concentrations at all times increased at least twofold with the increased surface area; highest observed concentrations were 0.17 and 0.41 ng/ml, respectively.",Influence of the method of application on pharmacokinetics of nitroglycerin from ointment in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6798193/),[ng] / [ml],0.17,214406,DB00727,Nitroglycerin
,6798193,highest observed concentrations,"Plasma concentrations at all times increased at least twofold with the increased surface area; highest observed concentrations were 0.17 and 0.41 ng/ml, respectively.",Influence of the method of application on pharmacokinetics of nitroglycerin from ointment in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6798193/),[ng] / [ml],0.41,214407,DB00727,Nitroglycerin
,6808113,bioavailability,"In applying this concept to nitroglycerin in rats, it was found that unrestricted rectal instillation of nitroglycerin (at 3.5-mg/kg dose) gave a mean +/-SD bioavailability of 26.7 +/- 7.0% (n=6) compared to 1.8 +/- 0.9% (n=5) from oral dosing.",Rectal absorption of nitroglycerin in the rat: avoidance of first-pass metabolism as a function of rectal length exposure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6808113/),%,26.7,217288,DB00727,Nitroglycerin
,6808113,bioavailability,"In applying this concept to nitroglycerin in rats, it was found that unrestricted rectal instillation of nitroglycerin (at 3.5-mg/kg dose) gave a mean +/-SD bioavailability of 26.7 +/- 7.0% (n=6) compared to 1.8 +/- 0.9% (n=5) from oral dosing.",Rectal absorption of nitroglycerin in the rat: avoidance of first-pass metabolism as a function of rectal length exposure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6808113/),%,1.8,217289,DB00727,Nitroglycerin
,6808113,bioavailability,"When the rectal exposure length to nitroglycerin was restricted to 3.5 cm from the anus, the mean +/-SD bioavailability increased to 83.5 +/- 74.5% (n=14).",Rectal absorption of nitroglycerin in the rat: avoidance of first-pass metabolism as a function of rectal length exposure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6808113/),%,83.5,217290,DB00727,Nitroglycerin
,6808113,bioavailability,"When the rectal exposure length was restricted to 2.0 cm from the anus (at 1.75-mg/kg dose), nitroglycerin bioavailability was estimated at 91.2 +/- 30.4% (n=6).",Rectal absorption of nitroglycerin in the rat: avoidance of first-pass metabolism as a function of rectal length exposure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6808113/),%,91.2,217291,DB00727,Nitroglycerin
,9587959,K1,"Nitroglycerin mean population parameter estimates and inter-individual variability (CV%) were: A 35% (65), K1 0.06 h-1(91), ka1 5 h-1(46), ka2 0.47 h-1(39), kf1 11 h-1(42), kf2 0.6 h-1(34), k(m) 1.4 h-1(29), V0/F 6 L(31), V2/F 73 L(34), and V3/F 23 L(29).",Novel pharmacokinetic modelling of transdermal nitroglycerin. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587959/),1/[h],0.06,218121,DB00727,Nitroglycerin
,9587959,ka1,"Nitroglycerin mean population parameter estimates and inter-individual variability (CV%) were: A 35% (65), K1 0.06 h-1(91), ka1 5 h-1(46), ka2 0.47 h-1(39), kf1 11 h-1(42), kf2 0.6 h-1(34), k(m) 1.4 h-1(29), V0/F 6 L(31), V2/F 73 L(34), and V3/F 23 L(29).",Novel pharmacokinetic modelling of transdermal nitroglycerin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587959/),1/[h],5,218122,DB00727,Nitroglycerin
,9587959,ka2,"Nitroglycerin mean population parameter estimates and inter-individual variability (CV%) were: A 35% (65), K1 0.06 h-1(91), ka1 5 h-1(46), ka2 0.47 h-1(39), kf1 11 h-1(42), kf2 0.6 h-1(34), k(m) 1.4 h-1(29), V0/F 6 L(31), V2/F 73 L(34), and V3/F 23 L(29).",Novel pharmacokinetic modelling of transdermal nitroglycerin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587959/),1/[h],0.47,218123,DB00727,Nitroglycerin
,9587959,kf1,"Nitroglycerin mean population parameter estimates and inter-individual variability (CV%) were: A 35% (65), K1 0.06 h-1(91), ka1 5 h-1(46), ka2 0.47 h-1(39), kf1 11 h-1(42), kf2 0.6 h-1(34), k(m) 1.4 h-1(29), V0/F 6 L(31), V2/F 73 L(34), and V3/F 23 L(29).",Novel pharmacokinetic modelling of transdermal nitroglycerin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587959/),1/[h],11,218124,DB00727,Nitroglycerin
,9587959,kf2,"Nitroglycerin mean population parameter estimates and inter-individual variability (CV%) were: A 35% (65), K1 0.06 h-1(91), ka1 5 h-1(46), ka2 0.47 h-1(39), kf1 11 h-1(42), kf2 0.6 h-1(34), k(m) 1.4 h-1(29), V0/F 6 L(31), V2/F 73 L(34), and V3/F 23 L(29).",Novel pharmacokinetic modelling of transdermal nitroglycerin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587959/),1/[h],0.6,218125,DB00727,Nitroglycerin
,9587959,k(m),"Nitroglycerin mean population parameter estimates and inter-individual variability (CV%) were: A 35% (65), K1 0.06 h-1(91), ka1 5 h-1(46), ka2 0.47 h-1(39), kf1 11 h-1(42), kf2 0.6 h-1(34), k(m) 1.4 h-1(29), V0/F 6 L(31), V2/F 73 L(34), and V3/F 23 L(29).",Novel pharmacokinetic modelling of transdermal nitroglycerin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587959/),1/[h],1.4,218126,DB00727,Nitroglycerin
,9587959,V0/F,"Nitroglycerin mean population parameter estimates and inter-individual variability (CV%) were: A 35% (65), K1 0.06 h-1(91), ka1 5 h-1(46), ka2 0.47 h-1(39), kf1 11 h-1(42), kf2 0.6 h-1(34), k(m) 1.4 h-1(29), V0/F 6 L(31), V2/F 73 L(34), and V3/F 23 L(29).",Novel pharmacokinetic modelling of transdermal nitroglycerin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587959/),l,6,218127,DB00727,Nitroglycerin
,9587959,V2/F,"Nitroglycerin mean population parameter estimates and inter-individual variability (CV%) were: A 35% (65), K1 0.06 h-1(91), ka1 5 h-1(46), ka2 0.47 h-1(39), kf1 11 h-1(42), kf2 0.6 h-1(34), k(m) 1.4 h-1(29), V0/F 6 L(31), V2/F 73 L(34), and V3/F 23 L(29).",Novel pharmacokinetic modelling of transdermal nitroglycerin. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587959/),l,73,218128,DB00727,Nitroglycerin
,9587959,V3/F,"Nitroglycerin mean population parameter estimates and inter-individual variability (CV%) were: A 35% (65), K1 0.06 h-1(91), ka1 5 h-1(46), ka2 0.47 h-1(39), kf1 11 h-1(42), kf2 0.6 h-1(34), k(m) 1.4 h-1(29), V0/F 6 L(31), V2/F 73 L(34), and V3/F 23 L(29).",Novel pharmacokinetic modelling of transdermal nitroglycerin. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587959/),l,23,218129,DB00727,Nitroglycerin
,9587959,elimination half-lives,"The average elimination half-lives for GTN and the two metabolites were 5 and 32 minutes, respectively.",Novel pharmacokinetic modelling of transdermal nitroglycerin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587959/),min,5,218130,DB00727,Nitroglycerin
,9587959,elimination half-lives,"The average elimination half-lives for GTN and the two metabolites were 5 and 32 minutes, respectively.",Novel pharmacokinetic modelling of transdermal nitroglycerin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9587959/),min,32,218131,DB00727,Nitroglycerin
,2124621,apparent clearance,"The mean apparent clearance after a low GTN i.v. dose (0.025 mg/kg) was 1440 ml/min/kg (S.D. = 630), which decreased to 686 ml/min/kg (S.D. = 317) after a high GTN i.v. dose (0.25 mg/kg), demonstrating dose-dependent pharmacokinetics.",Pharmacokinetics and pharmacodynamics of glyceryl trinitrate and its two dinitrate metabolites in conscious dogs. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2124621/),[ml] / [kg·min],1440,222080,DB00727,Nitroglycerin
,2124621,apparent clearance,"The mean apparent clearance after a low GTN i.v. dose (0.025 mg/kg) was 1440 ml/min/kg (S.D. = 630), which decreased to 686 ml/min/kg (S.D. = 317) after a high GTN i.v. dose (0.25 mg/kg), demonstrating dose-dependent pharmacokinetics.",Pharmacokinetics and pharmacodynamics of glyceryl trinitrate and its two dinitrate metabolites in conscious dogs. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2124621/),[ml] / [kg·min],686,222081,DB00727,Nitroglycerin
,2124621,Bioavailability,Bioavailability of oral GTN (0.25 mg/kg) was very low (0.015 +/- 0.019).,Pharmacokinetics and pharmacodynamics of glyceryl trinitrate and its two dinitrate metabolites in conscious dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2124621/),,0.015,222082,DB00727,Nitroglycerin
,2124621,half-lives,The dinitrates exhibited longer half-lives (approximately 45 min) and lower apparent clearances (approximately 16 ml/min/kg) than those found for GTN.,Pharmacokinetics and pharmacodynamics of glyceryl trinitrate and its two dinitrate metabolites in conscious dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2124621/),min,45,222083,DB00727,Nitroglycerin
,2124621,apparent clearances,The dinitrates exhibited longer half-lives (approximately 45 min) and lower apparent clearances (approximately 16 ml/min/kg) than those found for GTN.,Pharmacokinetics and pharmacodynamics of glyceryl trinitrate and its two dinitrate metabolites in conscious dogs. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2124621/),[ml] / [kg·min],16,222084,DB00727,Nitroglycerin
,2124621,"CLapp,m1","The CLapp,m1 decreased significantly (P less than .05) in going from the low GTN dose (1030 +/- 620 ml/min/kg) to the high dose (425 +/- 145 ml/min/kg).",Pharmacokinetics and pharmacodynamics of glyceryl trinitrate and its two dinitrate metabolites in conscious dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2124621/),[ml] / [kg·min],1030,222085,DB00727,Nitroglycerin
,2124621,"CLapp,m1","The CLapp,m1 decreased significantly (P less than .05) in going from the low GTN dose (1030 +/- 620 ml/min/kg) to the high dose (425 +/- 145 ml/min/kg).",Pharmacokinetics and pharmacodynamics of glyceryl trinitrate and its two dinitrate metabolites in conscious dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2124621/),[ml] / [kg·min],425,222086,DB00727,Nitroglycerin
,2124621,"CLapp,m2","In contrast, CLapp,m2 remained unchanged (low dose: 107 +/- 55 ml/min/kg; high dose: 115 +/- 37 ml/min/kg).",Pharmacokinetics and pharmacodynamics of glyceryl trinitrate and its two dinitrate metabolites in conscious dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2124621/),[ml] / [kg·min],107,222087,DB00727,Nitroglycerin
,2124621,"CLapp,m2","In contrast, CLapp,m2 remained unchanged (low dose: 107 +/- 55 ml/min/kg; high dose: 115 +/- 37 ml/min/kg).",Pharmacokinetics and pharmacodynamics of glyceryl trinitrate and its two dinitrate metabolites in conscious dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2124621/),[ml] / [kg·min],115,222088,DB00727,Nitroglycerin
,3082941,arteriovenous extraction,"Venous NTG concentrations were always lower than concurrent arterial concentrations, with an average arteriovenous extraction of 67.2%.",Influence of cardiopulmonary bypass on nitroglycerin clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082941/),%,67.2,229595,DB00727,Nitroglycerin
,3082941,apparent clearance,The mean +/- SD apparent clearance of NTG before bypass of 0.044 +/- 0.02 L/kg/min increased 20% to 0.052 +/- 0.02 L/kg/min during bypass (P = .05).,Influence of cardiopulmonary bypass on nitroglycerin clearance. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082941/),[l] / [kg·min],0.044,229596,DB00727,Nitroglycerin
,3082941,apparent clearance,The mean +/- SD apparent clearance of NTG before bypass of 0.044 +/- 0.02 L/kg/min increased 20% to 0.052 +/- 0.02 L/kg/min during bypass (P = .05).,Influence of cardiopulmonary bypass on nitroglycerin clearance. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082941/),[l] / [kg·min],0.052,229597,DB00727,Nitroglycerin
,3917598,bioavailability,"The mean bioavailability (+/- standard deviation) of sublingual nitroglycerin, estimated from plasma concentrations, was 36.2 +/- 24.9% (range 2.6 to 113%).",Incomplete and delayed bioavailability of sublingual nitroglycerin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3917598/),%,36.2,229907,DB00727,Nitroglycerin
,3917598,amount of drug not absorbed,"The amount of drug not absorbed after 8 minutes, as determined from the analysis of the mouth rinses, varied from 2.7 to 65.8% (mean 31.4 +/- 18.9%) of the administered sublingual dose.",Incomplete and delayed bioavailability of sublingual nitroglycerin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3917598/),%,31.4,229908,DB00727,Nitroglycerin
,3917598,peak concentrations,Mean nitroglycerin peak concentrations of 1.89 +/- 1.64 ng/ml were obtained at a mean peak time of 5.3 +/- 2.3 minutes.,Incomplete and delayed bioavailability of sublingual nitroglycerin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3917598/),[ng] / [ml],1.89,229909,DB00727,Nitroglycerin
,3917598,peak time,Mean nitroglycerin peak concentrations of 1.89 +/- 1.64 ng/ml were obtained at a mean peak time of 5.3 +/- 2.3 minutes.,Incomplete and delayed bioavailability of sublingual nitroglycerin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3917598/),min,5.3,229910,DB00727,Nitroglycerin
,3917598,peak times,"Thus, sublingual absorption is not instantaneous and can be relatively slow, with peak times of as long as 10 minutes.",Incomplete and delayed bioavailability of sublingual nitroglycerin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3917598/),min,10,229911,DB00727,Nitroglycerin
,3125063,maximal blood plasma concentration,The maximal blood plasma concentration of the drug was shown to occur on the average in 4.4 minutes and was 2.56 ng/ml.,[Pharmacokinetics of glycerin trinitrate (nitroglycerin) after sublingual administration in patients with chronic ischemic heart disease]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3125063/),[ng] / [ml],2.56,231229,DB00727,Nitroglycerin
,3125063,half-life,"The half-life in plasma was on the average 6.0 minutes, apparent clearance was 21.9 l/min.",[Pharmacokinetics of glycerin trinitrate (nitroglycerin) after sublingual administration in patients with chronic ischemic heart disease]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3125063/),min,6.0,231230,DB00727,Nitroglycerin
,3125063,apparent clearance,"The half-life in plasma was on the average 6.0 minutes, apparent clearance was 21.9 l/min.",[Pharmacokinetics of glycerin trinitrate (nitroglycerin) after sublingual administration in patients with chronic ischemic heart disease]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3125063/),[l] / [min],21.9,231231,DB00727,Nitroglycerin
,3125063,retention time,The mean retention time of nitroglycerin was 9.5 minutes.,[Pharmacokinetics of glycerin trinitrate (nitroglycerin) after sublingual administration in patients with chronic ischemic heart disease]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3125063/),min,9.5,231232,DB00727,Nitroglycerin
,7848350,area under the curve from time 0 to the last quantifiable sample (AUC(0-Tlast),"The investigation showed the following results: Metabolite 1,2-glyceryl dinitrate: For the area under the curve from time 0 to the last quantifiable sample (AUC(0-Tlast) arithmetic mean values of 23.77 h.ng/ml (test patch) and 27.83 h.ng/ml (reference patch) were found.","Bioequivalence evaluation of the metabolites 1,2 and 1,3-glyceryl dinitrate of two different glyceryl trinitrate patches after 12-h usage in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848350/),[h·ng] / [ml],23.77,234628,DB00727,Nitroglycerin
,7848350,area under the curve from time 0 to the last quantifiable sample (AUC(0-Tlast),"The investigation showed the following results: Metabolite 1,2-glyceryl dinitrate: For the area under the curve from time 0 to the last quantifiable sample (AUC(0-Tlast) arithmetic mean values of 23.77 h.ng/ml (test patch) and 27.83 h.ng/ml (reference patch) were found.","Bioequivalence evaluation of the metabolites 1,2 and 1,3-glyceryl dinitrate of two different glyceryl trinitrate patches after 12-h usage in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848350/),[h·ng] / [ml],27.83,234629,DB00727,Nitroglycerin
,7848350,peak plasma levels,"The corresponding peak plasma levels were 2.45 ng/ml and 2.93 ng/ml, respectively; they were reached after 6.4 h (test patch) and 8.31 h (reference patch).","Bioequivalence evaluation of the metabolites 1,2 and 1,3-glyceryl dinitrate of two different glyceryl trinitrate patches after 12-h usage in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848350/),[ng] / [ml],2.45,234630,DB00727,Nitroglycerin
,7848350,peak plasma levels,"The corresponding peak plasma levels were 2.45 ng/ml and 2.93 ng/ml, respectively; they were reached after 6.4 h (test patch) and 8.31 h (reference patch).","Bioequivalence evaluation of the metabolites 1,2 and 1,3-glyceryl dinitrate of two different glyceryl trinitrate patches after 12-h usage in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848350/),[ng] / [ml],2.93,234631,DB00727,Nitroglycerin
,7848350,AUC(0-Tlast),"Metabolite 1,3-glyceryl dinitrate: The arithmetic mean values for AUC(0-Tlast) were 3.32 h.ng/ml (test patch) and 3.81 h.ng/ml (reference patch).","Bioequivalence evaluation of the metabolites 1,2 and 1,3-glyceryl dinitrate of two different glyceryl trinitrate patches after 12-h usage in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848350/),[h·ng] / [ml],3.32,234632,DB00727,Nitroglycerin
,7848350,AUC(0-Tlast),"Metabolite 1,3-glyceryl dinitrate: The arithmetic mean values for AUC(0-Tlast) were 3.32 h.ng/ml (test patch) and 3.81 h.ng/ml (reference patch).","Bioequivalence evaluation of the metabolites 1,2 and 1,3-glyceryl dinitrate of two different glyceryl trinitrate patches after 12-h usage in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848350/),[h·ng] / [ml],3.81,234633,DB00727,Nitroglycerin
,7848350,maximum plasma levels,"The maximum plasma levels were 0.35 ng/ml and 0.41 ng/ml for the test and reference preparation, reached after 6.4 h and after 7.86 h, respectively.","Bioequivalence evaluation of the metabolites 1,2 and 1,3-glyceryl dinitrate of two different glyceryl trinitrate patches after 12-h usage in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848350/),[ng] / [ml],0.35,234634,DB00727,Nitroglycerin
,7848350,maximum plasma levels,"The maximum plasma levels were 0.35 ng/ml and 0.41 ng/ml for the test and reference preparation, reached after 6.4 h and after 7.86 h, respectively.","Bioequivalence evaluation of the metabolites 1,2 and 1,3-glyceryl dinitrate of two different glyceryl trinitrate patches after 12-h usage in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848350/),[ng] / [ml],0.41,234635,DB00727,Nitroglycerin
,6428208,ratio of maximum to minimum plasma levels,The ratio of maximum to minimum plasma levels during a dosing interval was 2 for oral Catapres and approximately 1 for Catapres -TTS.,Pharmacokinetics of nitroglycerin and clonidine delivered by the transdermal route. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6428208/),,2,242206,DB00727,Nitroglycerin
,6428208,ratio of maximum to minimum plasma levels,The ratio of maximum to minimum plasma levels during a dosing interval was 2 for oral Catapres and approximately 1 for Catapres -TTS.,Pharmacokinetics of nitroglycerin and clonidine delivered by the transdermal route. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6428208/),,1,242207,DB00727,Nitroglycerin
,6794970,plasma half-life,Mean plasma half-life was 2.15 hr and plasma clearance averaged 862 ml/min.,Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),h,2.15,249571,DB00727,Nitroglycerin
,6794970,plasma clearance,Mean plasma half-life was 2.15 hr and plasma clearance averaged 862 ml/min.,Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),[ml] / [min],862,249572,DB00727,Nitroglycerin
less,6794970,Peak plasma concentrations,Peak plasma concentrations ranged from less than 0.1 to 2 ng/ml.,Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),[ng] / [ml],0,249573,DB00727,Nitroglycerin
less,6794970,Peak plasma concentrations,Peak plasma concentrations ranged from less than 0.1 to 2 ng/ml.,Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),[ng] / [ml],2,249574,DB00727,Nitroglycerin
,6794970,Apparent oral absorption,Apparent oral absorption for DHE ranged from 19.5% to 53.3% while systemic bioavailability varied from less than 0.1% to 1.5%.,Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),%,19.5,249575,DB00727,Nitroglycerin
,6794970,Apparent oral absorption,Apparent oral absorption for DHE ranged from 19.5% to 53.3% while systemic bioavailability varied from less than 0.1% to 1.5%.,Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),%,53.3,249576,DB00727,Nitroglycerin
less,6794970,systemic bioavailability,Apparent oral absorption for DHE ranged from 19.5% to 53.3% while systemic bioavailability varied from less than 0.1% to 1.5%.,Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),%,0.1,249577,DB00727,Nitroglycerin
,6794970,systemic bioavailability,Apparent oral absorption for DHE ranged from 19.5% to 53.3% while systemic bioavailability varied from less than 0.1% to 1.5%.,Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),%,1.5,249578,DB00727,Nitroglycerin
,6794970,bioavailability,"when glyceryl trinitrate was taken orally with DHE, the bioavailability of the latter increased between 56% and 370% over the 0.1% to 1.5% without any apparent alteration in DHE absorption.",Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),%,56,249579,DB00727,Nitroglycerin
,6794970,bioavailability,"when glyceryl trinitrate was taken orally with DHE, the bioavailability of the latter increased between 56% and 370% over the 0.1% to 1.5% without any apparent alteration in DHE absorption.",Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),%,370,249580,DB00727,Nitroglycerin
,6794970,bioavailability,"when glyceryl trinitrate was taken orally with DHE, the bioavailability of the latter increased between 56% and 370% over the 0.1% to 1.5% without any apparent alteration in DHE absorption.",Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),%,0.1,249581,DB00727,Nitroglycerin
,6794970,bioavailability,"when glyceryl trinitrate was taken orally with DHE, the bioavailability of the latter increased between 56% and 370% over the 0.1% to 1.5% without any apparent alteration in DHE absorption.",Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6794970/),%,1.5,249582,DB00727,Nitroglycerin
,6414751,half-lives,"These metabolites have a good bioavailability, and half-lives of around 2.5 hours for isosorbide 2-mononitrate and 5 hours for isosorbide 5-mononitrate.",Clinical pharmacokinetics of organic nitrates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6414751/),h,2.5,257793,DB00727,Nitroglycerin
,6414751,half-lives,"These metabolites have a good bioavailability, and half-lives of around 2.5 hours for isosorbide 2-mononitrate and 5 hours for isosorbide 5-mononitrate.",Clinical pharmacokinetics of organic nitrates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6414751/),h,5,257794,DB00727,Nitroglycerin
,2517597,limit of detection,The described method is sensitive (limit of detection = 50 pg/ml of plasma) and sufficiently precise (error of the method = 13%).,[Determination of nitroglycerin in human plasma using gas chromatography after the administration of dosage forms used in Czechoslovakia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2517597/),[pg] / [ml],50,257889,DB00727,Nitroglycerin
,417170,half-life,"Nitroglycerin followed essentially one-compartment kinetics after intracardial administration, showing a mean half-life of about 4 min and a mean apparent volume of distribution of about 3 liters/kg.",Pharmacokinetics of nitroglycerin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/417170/),min,4,268811,DB00727,Nitroglycerin
,417170,apparent volume of distribution,"Nitroglycerin followed essentially one-compartment kinetics after intracardial administration, showing a mean half-life of about 4 min and a mean apparent volume of distribution of about 3 liters/kg.",Pharmacokinetics of nitroglycerin in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/417170/),[l] / [kg],3,268812,DB00727,Nitroglycerin
,417170,oral bioavailability,"The mean oral bioavailability was determined to be 1.6%, firmly supporting the contention that nitroglycerin is extensively metabolized during first passage through the liver.",Pharmacokinetics of nitroglycerin in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/417170/),%,1.6,268813,DB00727,Nitroglycerin
,27417951,elimination of half-life,"The parent drug concentrations rapidly decreased with an elimination of half-life of 1.6 h, and the metabolite initially increased and then decreased.",Severe Hypertension and Bradycardia Secondary to Midodrine Overdose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27417951/),h,1.6,272586,DB00727,Nitroglycerin
